var title_f26_28_27072="Urinary tract anatomy PI";
var content_f26_28_27072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Anatomy of the urinary tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine is made by the kidneys. It passes from the kidneys into the bladder through two tubes called the ureters. Then it leaves the bladder through another tube, called the urethra.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27072=[""].join("\n");
var outline_f26_28_27072=null;
var title_f26_28_27073="Needle technique for fish-hook removal";
var content_f26_28_27073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Needle technique of fish-hook removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 475px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Anesthetize the skin adjacent to the embedded fish-hook barb. B) Advance a large gauge needle through the skin so that it covers the barb (see inset). C) Back the fish-hook and needle out of the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Diekema DS. Fishhook removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27073=[""].join("\n");
var outline_f26_28_27073=null;
var title_f26_28_27074="Duane syndrome type 3";
var content_f26_28_27074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Duane syndrome of the left eye (type 3)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adduction and abduction of the involved left eye are limited.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27074=[""].join("\n");
var outline_f26_28_27074=null;
var title_f26_28_27075="Paratracheal mass MRI I";
var content_f26_28_27075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78631%7EPULM%2F56669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78631%7EPULM%2F56669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paratracheal mass due to primary lung adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T1-weighted section demonstrates a right paratracheal mass (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paratracheal mass due to primary lung adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial T1-weighted section demonstrates a right paratracheal mass. There are irregular margins with the lung parenchyma, consistent with either a pulmonary primary tumor or invasion of lung by a mediastinal tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27075=[""].join("\n");
var outline_f26_28_27075=null;
var title_f26_28_27076="Cross section ARPKD kidney";
var content_f26_28_27076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Cross-section of kidney from a patient with autosomal recessive kidney disease (ARPKD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross-section of a kidney from a patient with ARPKD demonstrates the cortical extension of fusiform or cylindrical spaces, which correspond to the dilated collecting tubules that radiate from the medulla to the cortex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27076=[""].join("\n");
var outline_f26_28_27076=null;
var title_f26_28_27077="Echocardiographic evaluation of the pericardium";
var content_f26_28_27077=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic evaluation of the pericardium",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27077/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27077/contributors\">",
"     Elyse Foster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27077/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27077/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27077/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27077/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/28/27077/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the method of choice for evaluating most pericardial diseases, given its ability to provide both anatomic and",
"    <span class=\"nowrap\">",
"     physiologic/hemodynamic",
"    </span>",
"    information. When competently performed in patients with good acoustic windows, echocardiography accurately detects pericardial effusions and provides clinically relevant information about their size and hemodynamic importance. The technique is less reliable than magnetic resonance imaging (MRI) and computed tomography (CT) in detecting pericardial",
"    <span class=\"nowrap\">",
"     thickening/constriction",
"    </span>",
"    and calcification as well as small loculated effusions, but can still be extremely useful in these conditions.",
"   </p>",
"   <p>",
"    A 2003 task force of the American College of Cardiology (ACC), the American Heart Association (AHA), and the American Society of Echocardiography (ASE) gave class I recommendations for the following uses of echocardiography in known or suspected pericardial disease (",
"    <a class=\"graphic graphic_table graphicRef80742 \" href=\"UTD.htm?4/0/4109\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27077/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with suspected pericardial disease, including effusion, constrictive pericarditis, or effusive-constrictive pericarditis.",
"     </li>",
"     <li>",
"      Patients with suspected bleeding into the pericardial space (eg, trauma, perforation).",
"     </li>",
"     <li>",
"      Follow-up study to evaluate recurrence of effusion following treatment or to diagnose early constrictive pericarditis. Repeat studies may be goal directed to answer a specific clinical question.",
"     </li>",
"     <li>",
"      Patients with pericardial friction rub developing in acute myocardial infarction accompanied by symptoms such as persistent pain, hypotension, and nausea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will discuss the echocardiographic approach to evaluating the pericardium, along with normal pericardial anatomy and a brief description of some pericardial pathologic processes. Detailed discussions of pericardial pathology, along with the imaging evaluation of the pericardium in particular disease states, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL PERICARDIUM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23111647\">",
"    <span class=\"h2\">",
"     Normal anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pericardium consists of two layers: a fibrous outer layer and a serous inner layer. The serous layer is a closed sac with the visceral component lining the epicardium and the parietal component lining the fibrous outer layer. The outer fibrous pericardium produces one of the most strongly reflective or echo-producing areas of the heart, and it normally moves anteriorly with the epicardium. The pericardium is reflected from the pulmonary veins as they enter the left atrium.",
"   </p>",
"   <p>",
"    Normally, a small amount of fluid (less than 25 to 50 mL) is contained within the closed sac of the serous layer. Because of the pericardial reflection at the level of the pulmonary veins, pericardial fluid rarely accumulates in this area because the potential space available decreases abruptly.",
"   </p>",
"   <p>",
"    Pericardial fat is also commonly seen on two-dimensional echocardiography. This normal but highly variable finding is most commonly seen anterior to the heart in the parasternal long axis view and in the subcostal views. The best clues to its identity as fat are its absence posteriorly, normal motion of the pericardium, and low intensity echoes (often seen as speckles) within the pericardial space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Echocardiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;When visualized on two-dimensional echocardiography, the layers of the pericardium appears as thin echogenic lines surrounding the myocardium. The normal thickness of the visualized pericardial layers is less than 1 to 2 mm, but it can be difficult to make accurate measurements on echocardiography.",
"   </p>",
"   <p>",
"    In the normal healthy pericardium, there is less than 25 to 50 mL of serous fluid in the pericardial sac formed by these layers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27077/abstract/2\">",
"     2",
"    </a>",
"    ]. The interposition of this fluid between the pericardial layers results in a very small separation of the layers, which is generally not visible by two-dimensional echocardiography. However, this small physiologic separation can be appreciated on M-mode echocardiography, although it is obvious only during systole (",
"    <a class=\"graphic graphic_figure graphicRef61898 \" href=\"UTD.htm?30/0/30725\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When inspecting the pericardium in a real time two-dimensional examination, it is important to appreciate the motion of the heart within it. Normally, the heart and epicardial pericardium move and twist within the parietal pericardium. In the short axis, the motion is due to the torsion of the heart during systole and in the four chamber view to both the torsion and the longitudinal muscle shortening. This normal independent motion is impaired or lost when pericardial inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    scarring results in adhesions between the layers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23111719\">",
"    <span class=\"h1\">",
"     CONDITIONS ASSOCIATED WITH PERICARDIAL PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial abnormalities can result from a number of cardiac and systemic conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acute pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiogram is often normal in patients with the clinical syndrome of acute pericarditis unless it is associated with a pericardial effusion. While the finding of a pericardial effusion in a patient with known or suspected pericarditis supports the diagnosis, the absence of a pericardial effusion or other echocardiographic abnormalities does not exclude it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link&amp;anchor=H2298690#H2298690\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\", section on 'Echocardiogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pericardial effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography has an important role in diagnosing the presence of pericardial effusion, estimating the size of the effusion, and evaluating the hemodynamic importance of any effusion (",
"    <a class=\"graphic graphic_movie graphicRef76287 \" href=\"UTD.htm?10/29/10708\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef77900 \" href=\"UTD.htm?25/51/26430\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66715 \" href=\"UTD.htm?31/42/32420\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef74765 \" href=\"UTD.htm?37/37/38483\">",
"     movie 4",
"    </a>",
"    ). Echocardiography is also helpful to determine if the effusion can be approached percutaneously and to assist monitoring during pericardiocentesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=see_link\">",
"     \"Technique of pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Loculated effusion and other post operative sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial fluid ceases to be circumferential and free flowing and becomes loculated or compartmentalized as a result of a variety of disease processes (",
"    <a class=\"graphic graphic_movie graphicRef73179 \" href=\"UTD.htm?26/14/26863\">",
"     movie 5",
"    </a>",
"    ), most commonly following cardiac surgery or following pericardial hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=see_link\">",
"     \"Post-cardiac injury syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Differentiating between pleural and pericardial effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left pleural effusions can present as large echo-free spaces that resemble pericardial effusion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66726 \" href=\"UTD.htm?15/61/16351\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef88546 \" href=\"UTD.htm?27/14/27873\">",
"     movie 6",
"    </a>",
"    ). These can be recognized because they appear as very large posterior spaces without any anterior component. Generally, in the parasternal long axis view, pleural effusions are located posterior to the descending aorta, while pericardial effusions are located anterior to the aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Pericardial thickening and constriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial thickening is a commonly encountered echocardiographic finding, but hemodynamically important thickening resulting in constrictive pericarditis is relatively rare. While MRI and CT are both superior techniques for detecting pericardial thickening, echocardiography can also be useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link&amp;anchor=H274012956#H274012956\">",
"     \"Constrictive pericarditis\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Pericardial constriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;If pericardial thickening persists",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fails to resolve, chronic pericardial thickening with constrictive pericarditis can develop. Like cardiac tamponade, constrictive pericarditis is a continuum of impairment of cardiac function that causes restraint or restriction on ventricular filling sufficient to decrease cardiac output or cardiac reserve. Advances in Doppler echocardiography for the detection of constrictive pericarditis have improved the noninvasive detection of this clinical entity, but, as with the distinction between cardiac tamponade and pericardial effusion, there can be significant overlap between the findings in frank constriction and those in extensive pericardial thickening without hemodynamic compromise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link&amp;anchor=H13#H13\">",
"     \"Constrictive pericarditis\", section on 'Echocardiography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link&amp;anchor=H7#H7\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\", section on 'Non-invasive testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Tumors of the pericardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized pericardial thickening or the presence of a pericardial effusion can represent manifestation of primary pericardial malignancy, the result of a pericardial tumor from metastatic disease, or contiguous encroachment of a non-cardiac tumor into the pericardial space [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27077/abstract/3\">",
"     3",
"    </a>",
"    ]. If a large tumor invades locally from the lateral chest, it is often possible to appreciate a locally dense area along the lateral border of the heart. The telling characteristic of these masses is often their seeming immobility during the cardiac cycle; as the heart abuts these masses, they seem fixed in space. Thoracic MRI or CT are often helpful in characterizing mediastinal masses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Absence of the pericardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pericardium exerts considerable influence on cardiac motion, providing stability to the location of the heart in the chest, and limits the dilatation of the chambers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Pericardial disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Surgical removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;After surgical removal of the pericardium, the heart frequently expands, and the posterior left ventricular wall motion may become exaggerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Congenital absence of the pericardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete and partial absence of the pericardium is associated with the enlargement of the right ventricle, excessive motion of the posterior left ventricular wall, and shift of the heart to the left, resulting in more of the right ventricle being seen on the routine left parasternal echocardiogram. These changes may result in paradoxical motion of the interventricular septum. All of these findings mimic right ventricular volume overload as seen in atrial septal defect or tricuspid insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27077/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27766?source=see_link\">",
"     \"Echocardiographic evaluation of the right ventricle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Partial absence of the pericardium sometimes results in herniation of a chamber through the defect. At the site of herniation, the false appearance of a wall motion abnormality can be created along the line of demarcation. However, if a coronary artery is compressed, a true wall motion abnormality may indeed exist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Pericardial cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a pericardial cyst is usually suggested by the chest radiograph. Pericardial cysts often occur at the right atrial border and are difficult to detect with transthoracic echocardiography; they may be more readily visualized with transesophageal echocardiography and present as an echo-free space that is more localized and spherical than a pericardial effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27077/abstract/5\">",
"     5",
"    </a>",
"    ]. Both thoracic MRI and CT are preferred methods to confirm a suspected diagnosis of pericardial cyst. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=see_link&amp;anchor=H19#H19\">",
"     \"Anterior mediastinal mass lesions\", section on 'Pericardial cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34577?source=see_link\">",
"       \"Patient information: Cardiac tamponade (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       \"Patient information: Pericarditis (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23112616\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiography is the method of choice for evaluating most pericardial diseases, given its ability to provide both anatomic and",
"      <span class=\"nowrap\">",
"       physiologic/hemodynamic",
"      </span>",
"      information. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The normal pericardium consists of two layers: a fibrous outer layer and a serous inner layer. Normally, a small amount of fluid (less than 25 to 50 mL) is contained within the closed sac of the serous layer. (See",
"      <a class=\"local\" href=\"#H23111647\">",
"       'Normal anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When visualized on two-dimensional echocardiography, the layers of the pericardium appears as thin echogenic lines surrounding the myocardium. The normal thickness of the visualized pericardial layers is less than 1 to 2 mm. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Echocardiographic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericardial abnormalities can result from a number of cardiac and systemic conditions, including acute pericarditis, pericardial effusion, cardiac tamponade, constrictive pericarditis, pericardial tumors, and pericardial cysts, among others. (See",
"      <a class=\"local\" href=\"#H23111719\">",
"       'Conditions associated with pericardial pathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1146374661\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Nelson Schiller, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline for the clinical application of echocardiography www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27077/abstract/2\">",
"      Horowitz MS, Schultz CS, Stinson EB, et al. Sensitivity and specificity of echocardiographic diagnosis of pericardial effusion. Circulation 1974; 50:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27077/abstract/3\">",
"      Chandraratna PA, Aronow WS. Detection of pericardial metastases by cross-section echocardiography. Circulation 1981; 63:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27077/abstract/4\">",
"      Payvandi MN, Kerber RE. Echocardiography in congenital and acquired absence of the pericardium. An echocardiographic mimic of right ventricular volume overload. Circulation 1976; 53:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27077/abstract/5\">",
"      Hynes JK, Tajik AJ, Osborn MJ, et al. Two-dimensional echocardiographic diagnosis of pericardial cyst. Mayo Clin Proc 1983; 58:60.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5299 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-AFC96612BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27077=[""].join("\n");
var outline_f26_28_27077=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23112616\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL PERICARDIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23111647\">",
"      Normal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Echocardiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23111719\">",
"      CONDITIONS ASSOCIATED WITH PERICARDIAL PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Loculated effusion and other post operative sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Differentiating between pleural and pericardial effusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Pericardial thickening and constriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Pericardial constriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Tumors of the pericardium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Absence of the pericardium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Surgical removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Congenital absence of the pericardium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Pericardial cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23112616\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1146374661\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5299\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5299|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/61/16351\" title=\"diagnostic image 1\">",
"      Pericardial pleural effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5299|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/0/30725\" title=\"figure 1\">",
"      M mode echo parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5299|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/29/10708\" title=\"movie 1\">",
"      Pericardial effusion parasternal long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?25/51/26430\" title=\"movie 2\">",
"      Pericardial effusion without tamponade 4 chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?31/42/32420\" title=\"movie 3\">",
"      Pericardial effusion four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?37/37/38483\" title=\"movie 4\">",
"      Pericardial effusion with tamponade subcostal echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?26/14/26863\" title=\"movie 5\">",
"      Pericardial effusion subcostal echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?27/14/27873\" title=\"movie 6\">",
"      2D TTE parasternal long axis pleural and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5299|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/0/4109\" title=\"table 1\">",
"      Echo pericardial disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=related_link\">",
"      Anterior mediastinal mass lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27766?source=related_link\">",
"      Echocardiographic evaluation of the right ventricle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34577?source=related_link\">",
"      Patient information: Cardiac tamponade (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=related_link\">",
"      Post-cardiac injury syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=related_link\">",
"      Technique of pericardiocentesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_28_27078="Distribution vector ticks";
var content_f26_28_27078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Approximate distribution of vector tick species for human monocytotropic ehrlichiosis and human granulocytotropic anaplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 493px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Champman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis -- United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27078=[""].join("\n");
var outline_f26_28_27078=null;
var title_f26_28_27079="Management of ureteral calculi";
var content_f26_28_27079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of ureteral calculi",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27079/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27079/contributors\">",
"     Glenn M Preminger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27079/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27079/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27079/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27079/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27079/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/28/27079/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of spontaneous passage of a ureteral stone is related to both stone size and location. Most stones &le;4 mm in diameter pass spontaneously. Stone diameter &ge;5 mm is associated with a progressive decrease in the spontaneous passage rate, which is unlikely with stones &ge;10 mm in diameter. Proximal ureteral stones are also less likely to pass spontaneously. The data supporting these conclusions are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of ureteral calculi by stone location within the ureter will be reviewed here. Further discussion regarding the techniques utilized to treat ureteral calculi (including associated complications), the diagnosis and acute management of nephrolithiasis, and the significance of residual stones after stone removal are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30756?source=see_link\">",
"     \"Clinical significance of residual stone fragments following stone removal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21125903\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach of managing ureteral calculi varies with the size and location of the stone, and the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    absence of patient comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21126001\">",
"    <span class=\"h2\">",
"     Emergency therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In septic patients with obstructing stones, urgent decompression of the collecting system with either percutaneous drainage or ureteral stenting is indicated in combination with appropriate antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/1\">",
"     1",
"    </a>",
"    ]. Definitive treatment of the stone should be delayed until sepsis is resolved. Additional indications for urgent decompression include bilateral obstruction with acute kidney injury and unilateral obstruction with acute kidney injury in a solitary kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21126008\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient who has a newly diagnosed ureteral stone &lt;10 mm and whose symptoms are controlled, observation with periodic evaluation is an option for initial treatment. Such patients may be offered an appropriate medical therapy to facilitate stone passage during the observation period. Patients who elect for an attempt at spontaneous passage or medical expulsive therapy should have well controlled pain, no clinical evidence of sepsis, and adequate renal functional reserve. Patients should be followed with periodic imaging studies to monitor stone position and to assess for hydronephrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=see_link\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21126027\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients in whom emergency therapy is not indicated, stone removal may be performed in the presence of persistent obstruction, failure of stone progression, or in the presence of increasing or unremitting colic. The ureteral stone that must be removed requires the use of a modality such as lithotripsy or endoscopic removal. Developments in shock-wave lithotripsy technologies, with electrohydraulic and laser lithotripsy, have improved intracorporeal stone fragmentation. Advances in endoscopic modalities, with the development of rigid, and later, semi-rigid and flexible fiberoptic ureteroscopes, has made the entire ureter and renal pelvis accessible for the treatment of ureteral and renal stones [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/2\">",
"     2",
"    </a>",
"    ]. Advances in the fiberoptic lens systems enabled manufacture of smaller ureteroscopes that can traverse the ureter without prior dilation. The use of a ureteral access sheath has greatly simplified passage of the ureteroscope, thereby facilitating ureteroscopic access to the mid- and proximal ureter, as well as to the intrarenal collecting system [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13011188\">",
"    <span class=\"h3\">",
"     Ureteroscopy versus shock wave lithotripsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteroscopy and shock wave lithotripsy (SWL) are the two most commonly used surgical techniques in patients who require removal of ureteral stones. Available data, including the meta-analysis discussed below, suggest that ureteroscopy should be considered the first line treatment for the management of most calculi requiring surgical removal, especially in patients with large ureteral stones or complex renal anatomy and in patients who are obese or have a high risk of bleeding. SWL may be as effective as ureteroscopy for the treatment for small (less than 1 cm) stones in the proximal ureter.",
"   </p>",
"   <p>",
"    The outcomes associated with ureteroscopy and SWL were compared in a meta-analysis of seven randomized trials including 1205 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/4\">",
"     4",
"    </a>",
"    ]. These trials were heterogenous with respect to duration of follow-up (two weeks to three months), stone location (proximal ureteral in two, mid-ureteral in one, and distal ureteral in four), type of ureteroscope, and type of lithotriptor. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The stone-free rate was significantly better with ureteroscopy as compared with SWL (92 versus 77 percent).",
"     </li>",
"     <li>",
"      In addition, the need for retreatment was significantly lower with ureteroscopy (3 versus 21 percent).",
"     </li>",
"     <li>",
"      However, procedure-related complications were significantly more frequent with ureteroscopy (16 versus 9 percent), although most complications were minor and required no intervention. In addition, ureteroscopy required longer hospital stays (by 2.5 days); however, hospitalization after ureteroscopy was routine practice in countries where some of the trials were performed but is",
"      <strong>",
"       not",
"      </strong>",
"      routine in the United States.",
"     </li>",
"     <li>",
"      Postoperative symptoms were similar between the groups, although patients assigned SWL required more postoperative analgesia.",
"     </li>",
"     <li>",
"      Although the superiority of ureteroscopy did not appear to be influenced by the ureteral location of the stone, only two trials examined patients with proximal ureteral stones and only one enrolled patients with small proximal calculi. This trial was characterized by a high risk of bias, including concerns about randomization and blinding. Thus, it is not clear that ureteroscopy is superior to SWL for treatment of small stones in the proximal ureter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second meta-analysis, which included most of the same trials, reached similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition to the data presented above, stone size and patient characteristics must be considered in choosing a modality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large stones (greater than 10 mm in diameter) may be difficult to treat with SWL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link&amp;anchor=H10#H10\">",
"       \"Options in the management of renal and ureteral stones in adults\", section on 'Shock wave lithotripsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stones in patients with complex renal anatomy or complex stones are more easily fragmented with ureteroscopy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link&amp;anchor=H10#H10\">",
"       \"Options in the management of renal and ureteral stones in adults\", section on 'Shock wave lithotripsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Massive bleeding of the liver and spleen has been reported with shock wave lithotripsy; by comparison, such hemorrhagic complications have not been observed with ureteroscopy, even in patients with significant coagulopathies. Thus, ureteroscopy may be preferred in patients at increased risk of significant bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The efficacy of SWL is decreased in obese patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/7\">",
"       7",
"      </a>",
"      ]. Thus, ureteroscopy is preferred in such patients.",
"     </li>",
"     <li>",
"      Ureteroscopy is often necessary for the management of ureteral calculi that have failed shock wave lithotripsy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/8\">",
"       8",
"      </a>",
"      ]. Percutaneous nephrolithotomy or laparoscopy offer minimally invasive treatment options for the removal of large or severely impacted ureteral calculi [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/2,9\">",
"       2,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of the benefits and complications of surgical modalities associated with stone removal is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROXIMAL URETERAL CALCULI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The options for the treatment of proximal ureteral calculi include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Various first and second generation lithotriptors, which utilize fluoroscopic and ultrasound imaging systems",
"     </li>",
"     <li>",
"      Flexible ureteroscopy",
"     </li>",
"     <li>",
"      Percutaneous antegrade techniques",
"     </li>",
"     <li>",
"      Retroperitoneal laparoscopy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Shock wave lithotripsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of centers use in situ shock wave lithotripsy (SWL) monotherapy to treat proximal ureteral stones [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/10\">",
"     10",
"    </a>",
"    ]. With upper ureteral stones, first and second generation lithotriptors that employ fluoroscopy reportedly achieve stone-free rates between 60 and 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/11\">",
"     11",
"    </a>",
"    ]. SWL can occasionally be tedious with second generation units in which ultrasound is used for localization. Decreasing the shock wave rate from 120 to 60 shocks per minute may result in a significant increase in stone free rates, from 49 to 65 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proximal ureteral calculi may be pushed into the renal pelvis to facilitate SWL visualization, targeting, and fragmentation (the so-called \"push-bang\" technique). Placement of a ureteral stent also appears to aid in the fragmentation and visualization of the stone.",
"   </p>",
"   <p>",
"    SWL is most effective in fragmenting small (&le;1 cm in diameter) calcium stones [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. By comparison, the technique leaves residual stone fragments in approximately 35 to 55 percent of patients with larger renal stones [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Adjunctive measures may increase the passage rate of ureteral stone fragments following shock wave lithotripsy. In an open label trial, patients with single proximal ureteral calculi were randomly assigned to receive either 0.4 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    or no therapy during treatment of their stones [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/17\">",
"     17",
"    </a>",
"    ]. The stone-free rate was significantly higher in the patients treated with tamsulosin (55 versus 25 percent). However, this treatment did not appear to provide a significant advantage in terms of decreasing pain associated with SWL treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Flexible ureteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral access sheaths allow for rapid and safe passage of the flexible ureteroscope into the proximal ureter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, proximal ureteral calculi may be approached endoscopically and fragmented primarily with holmium laser lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/18\">",
"     18",
"    </a>",
"    ]. Electrohydraulic lithotripsy for stone fragmentation is rarely used today.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Holmium laser lithotripsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser lithotripsy of proximal ureteral calculi has proven to be highly effective and is considered by many urologists the treatment of choice for stones in this location. Fragmentation rates for cystine and calcium oxalated monohydrate calculi, which were difficult to treat with early laser prototypes, have been greatly improved with larger, higher power laser fibers and through the use the holmium laser [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/19\">",
"     19",
"    </a>",
"    ]. Stone-free rates are reported to be near 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/16,20-22\">",
"     16,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some evidence suggests that stone fragments produced by holmium laser lithotripsy should be actively retrieved and removed during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/23\">",
"     23",
"    </a>",
"    ]. This was demonstrated in 60 patients undergoing ureteroscopy and holmium laser lithotripsy who were randomly assigned to either intraoperative fragment retrieval or to exhaustive lithotripsy with anticipated spontaneous fragment expulsion during the post operative period. Patients who did not have intraoperative fragment retrieval had the following adverse outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly higher rate of unplanned visits to the emergency department (3 versus 30 percent, OR 12.4, 95% CI 1.8-80.3)",
"     </li>",
"     <li>",
"      Trends toward higher rates of rehospitalization (0 versus 10 percent, p = 0.24), need for ancillary treatment (0 versus 7 percent, p = 0.49), and lower stone-free rate (100 versus 87 percent, p = 0.1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that not actively retrieving fragments during ureteroscopy and holmium laser lithotripsy is associated with a higher risk of morbidity and medical utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, it is now our practice to actively retrieve all stone fragments during ureteroscopic holmium laser stone fragmentation.",
"   </p>",
"   <p>",
"    Fragment retrieval can be facilitated by deploying various &ldquo;backstop&rdquo; devices proximal to the stone prior to fragmentation to prevent them from migrating back into the renal pelvis. This technique was tested in a randomized trial of 113 patients with large proximal ureteral calculi [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/24\">",
"     24",
"    </a>",
"    ]. Compared with patients who did not have backstop devices placed above the stone, those with deployed devices during surgery had significantly lower rates of fragment migration into the renal pelvis (0 versus 12 percent), and trends toward higher stone free rates (100 versus 91 percent), lower rates of hospitalization (0 versus 4 percent), and fewer visits to the emergency department (7 versus 12 percent).",
"   </p>",
"   <p>",
"    The use of ureteroscopy with intracorporeal lithotripsy is highly effective in treating stones &gt;1 cm in diameter and appears to be superior to lithotripsy in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/16\">",
"     16",
"    </a>",
"    ]. Combined treatment with flexible ureteroscopy and holmium laser lithotripsy can also be used for the removal of very large (&gt;2 to 3 cm in diameter) or impacted stones [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Percutaneous antegrade approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The percutaneous antegrade approach is another viable treatment option. In one series, 35 of 37 proximal ureteral calculi and 20 of 20 mid-ureteral calculi were successfully removed intact by flexible nephroscopy, fragmented with either electrohydraulic or ultrasonic lithotripsy, or basketed under fluoroscopic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/2\">",
"     2",
"    </a>",
"    ]. The percutaneous approach is usually reserved for large, impacted proximal ureteral calculi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Retroperitoneal laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal laparoscopy is a viable option for very large or severely impacted mid- or proximal ureteral calculi. Success rates of 100 percent with minimal patient morbidity have been reported when utilizing established laparoscopic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/9,26\">",
"     9,26",
"    </a>",
"    ]. In a randomized trial of 48 patients with proximal or mid-ureteral stones requiring surgical removal, stone removal with both the antegrade approach and the retroperitoneal approach were equally successful; however, the retroperitoneal approach was associated with less postoperative pain, a lower incidence of paralytic ileus, and shorter hospitalizations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For small proximal ureteral calculi (less than 10 mm), shock wave lithotripsy and ureteroscopy are both considered first line therapy. However, with proximal ureteral stones that are larger than 10 mm, flexible ureteroscopy combined with holmium laser lithotripsy and intraoperative fragment retrieval offers optimal results [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/16,25,28\">",
"     16,25,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MID-URETERAL CALCULI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of calculi in the mid-ureter has become significantly less troublesome with the advent of the flexible ureteroscope and associated instrumentation used for in situ fragmentation. With improved fluoroscopic imaging, shock wave lithotripsy (SWL) can now be used for mid-ureteral stone fragmentation.",
"   </p>",
"   <p>",
"    Early studies reported low stone-free rates for mid-ureteral calculi using SWL. These relatively poor results appear to be due in part to patient position when treated. As an example, with the patient in the prone position, one series reported a 94 percent stone-free rate with treatment on the HM-3 lithotriptor. This position decreases the attenuation of shock waves that is normally encountered with traditional shock wave entry through the patient's back.",
"   </p>",
"   <p>",
"    Because of the bony pelvis and sacrum as well as the lack of easily identified sonographic landmarks, SWL of mid-ureteral calculi using second generation ultrasound-guided lithotriptors has presented significant difficulty. Despite these problems, some series have reported stone-free rates in excess of 75 percent for in situ treatment of mid-ureteral stones using ultrasound-guided lithotriptors. As with proximal ureteral stones, mid-ureteral calculi may be pushed into the renal pelvis for \"routine\" shock wave lithotripsy.",
"   </p>",
"   <p>",
"    Mid-ureteral stones are easily accessible by both rigid and flexible ureteroscopy. Small diameter semi-rigid fiberoptic ureteroscopes obviate the need for dilatation while providing excellent optics, thereby enabling the urologist to treat ureteral calculi in a minimally invasive fashion, and in select cases, under only sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/29\">",
"     29",
"    </a>",
"    ]. In most series, stones in the mid-ureter that are treated with ureteroscopy are removed in 80 to 95 percent of cases with electrohydraulic lithotripsy, laser, or pneumatic lithotripsy, with or without basketing. A number of less expensive, low power holmium lasers are now available, making laser stone fragmentation the preferred method of stone removal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The highest stone-free rates and lowest number of required re-treatments are associated with ureteroscopy with holmium laser lithotripsy. Thus, flexible ureteroscopy is generally preferred over in situ SWL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DISTAL URETERAL STONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many clinicians, ureteroscopy is the preferred treatment of distal ureteral calculi. However, shock wave lithotripsy (SWL) is used in some centers.",
"   </p>",
"   <p>",
"    Several investigators have advocated the use of SWL, with the patient in a prone or modified sitting position, for the treatment of distal and prevesicular stones. One study found an 87 percent stone-free rate with one treatment on the HM-3 lithotriptor, when patients were positioned in the prone position. Similar results have been noted in other series using the Dornier HM-3 lithotriptor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of distal ureteral stones with rigid ureteroscopy has also proven to be reliable and safe; it requires less technical expertise than with more proximal calculi [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/32\">",
"     32",
"    </a>",
"    ]. Lower ureteral stones can be removed by ureteroscopy in approximately 90 to 99 percent of cases. Compared with SWL, ureteroscopy produces superior stone-free rates. (See",
"    <a class=\"local\" href=\"#H13011188\">",
"     'Ureteroscopy versus shock wave lithotripsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Laser lithotripsy is currently considered the method of choice for intraurethral fragmentation, and is also effective in greater than 95 percent of distal ureteral stones [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many clinicians routinely place a ureteral stent following ureteroscopic management of distal ureteral calculi to minimize postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the absence of stent placement appears to be safe during uncomplicated procedures and may be associated with less pain and fewer urinary symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators believe the treatment of distal ureteral stones may best be managed initially with endoscopic techniques, and this is supported by meta-analyses of randomized trials. However, SWL is utilized by some clinicians. Failure of both treatment options may require antegrade percutaneous management or (in extremely rare cases) open or laparoscopic ureterolithotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECURRENT STONE FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even after successful therapy, the stone-free rate is generally only about 75 percent at 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27079/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, patients with active stone disease should undergo evaluation for, and appropriate treatment of, metabolic abnormalities that predispose to stone formation, such as hypercalciuria, hyperuricosuria, or hypocitraturia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\", section on 'The complete metabolic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30756?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical significance of residual stone fragments following stone removal\", section on 'Medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"       \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16847592\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal approach of managing ureteral calculi varies with the size and location of the stone, and the presence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      absence of patient comorbidities:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Emergency therapy",
"      </strong>",
"      - Urgent decompression of the collecting system with either percutaneous drainage or ureteral stenting is indicated in septic patients with obstructing stones, bilateral obstruction with acute kidney injury, and unilateral obstruction with acute kidney injury in a solitary kidney. (See",
"      <a class=\"local\" href=\"#H21126001\">",
"       'Emergency therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Medical therapy",
"      </strong>",
"      - In a patient who has a newly diagnosed ureteral stone &lt;10 mm and whose symptoms are controlled, observation with periodic evaluation is an option for initial treatment. Patients who elect for an attempt at spontaneous passage or medical expulsive therapy should have well controlled pain, no clinical evidence of sepsis, and adequate renal functional reserve. (See",
"      <a class=\"local\" href=\"#H21126008\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Surgical therapy",
"      </strong>",
"      - In patients in whom emergency therapy is not indicated, stone removal may be performed in the presence of persistent obstruction, failure of stone progression, or in the presence of increasing or unremitting colic. In patients who require stone removal, the two most commonly applied techniques are ureteroscopy and shock wave lithotripsy (SWL). Ureteroscopy produces better stone-free rates and a reduced need for retreatment. (See",
"      <a class=\"local\" href=\"#H21126027\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of",
"      <strong>",
"       proximal",
"      </strong>",
"      <strong>",
"       ureteral calculi",
"      </strong>",
"      depends upon the size of the stone. For small proximal ureteral calculi (less than 10 mm), SWL and ureteroscopy are both considered first line therapy. However, with proximal ureteral stones that are larger than 10 mm, flexible ureteroscopy combined with holmium laser lithotripsy and intraoperative fragment retrieval offers optimal results. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Proximal ureteral calculi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For",
"      <strong>",
"       mid-ureteral stones",
"      </strong>",
"      , the highest stone-free rates and lowest number of required re-treatments are seen with ureteroscopy with holmium laser lithotripsy; thus, flexible ureteroscopy is generally preferred over SWL. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mid-ureteral calculi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best initial option for the treatment of",
"      <strong>",
"       distal ureteral stones",
"      </strong>",
"      is ureteroscopy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Distal ureteral stones'",
"      </a>",
"      above.) However, stone-free rates are high with both techniques and some clinicians prefer SWL.",
"     </li>",
"     <li>",
"      Other surgical techniques, including percutaneous anterograde ureteroscopy and retroperitoneal laparoscopy, are usually reserved for large, impacted ureteral calculi when less invasive techniques are unlikely to be successful. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Percutaneous antegrade approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Retroperitoneal laparoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with active stone disease should undergo evaluation for, and appropriate treatment of, metabolic abnormalities that predispose to stone formation, such as hypercalciuria, hyperuricosuria, or hypocitraturia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Recurrent stone formation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/1\">",
"      Borofsky MS, Walter D, Shah O, et al. Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi. J Urol 2013; 189:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/2\">",
"      Segura JW, Preminger GM, Assimos DG, et al. Ureteral Stones Clinical Guidelines Panel summary report on the management of ureteral calculi. The American Urological Association. J Urol 1997; 158:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/3\">",
"      Kourambas J, Byrne RR, Preminger GM. Does a ureteral access sheath facilitate ureteroscopy? J Urol 2001; 165:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/4\">",
"      Aboumarzouk OM, Kata SG, Keeley FX, et al. Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi. Cochrane Database Syst Rev 2012; 5:CD006029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/5\">",
"      Matlaga BR, Jansen JP, Meckley LM, et al. Treatment of ureteral and renal stones: a systematic review and meta-analysis of randomized, controlled trials. J Urol 2012; 188:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/6\">",
"      Irwin BH, Desai M. Ureteroscopic superiority to extracorporeal shock wave lithotripsy for the treatment of small-to-medium-sized intrarenal non-staghorn calculi. Urology 2009; 74:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/7\">",
"      Pareek G, Armenakas NA, Panagopoulos G, et al. Extracorporeal shock wave lithotripsy success based on body mass index and Hounsfield units. Urology 2005; 65:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/8\">",
"      Preminger GM. Technique versus technology: what is the most appropriate method for the removal of ureteral calculi. J Urol 1994; 152:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/9\">",
"      Hemal AK, Goel A, Goel R. Minimally invasive retroperitoneoscopic ureterolithotomy. J Urol 2003; 169:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/10\">",
"      Fetner CD, Preminger GM, Seger J, Lea TA. Treatment of ureteral calculi by extracorporeal shock wave lithotripsy at a multi-use center. J Urol 1988; 139:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/11\">",
"      Goethuys H, Winnepenninckx B, Van Poppel H, Baert L. The new generation Siemens Multiline lithotripter tube \"M\": early results in ureteral calculi. J Endourol 1996; 10:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/12\">",
"      Honey RJ, Schuler TD, Ghiculete D, et al. A randomized, double-blind trial to compare shock wave frequencies of 60 and 120 shocks per minute for upper ureteral stones. J Urol 2009; 182:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/13\">",
"      Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/14\">",
"      Smith LH, Drach G, Hall P, et al. National High Blood Pressure Education Program (NHBPEP) review paper on complications of shock wave lithotripsy for urinary calculi. Am J Med 1991; 91:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/15\">",
"      Ehreth JT, Drach GW, Arnett ML, et al. Extracorporeal shock wave lithotripsy: multicenter study of kidney and upper ureter versus middle and lower ureter treatments. J Urol 1994; 152:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/16\">",
"      Salem HK. A prospective randomized study comparing shock wave lithotripsy and semirigid ureteroscopy for the management of proximal ureteral calculi. Urology 2009; 74:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/17\">",
"      Agarwal MM, Naja V, Singh SK, et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology 2009; 74:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/18\">",
"      Erhard M, Salwen J, Bagley DH. Ureteroscopic removal of mid and proximal ureteral calculi. J Urol 1996; 155:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/19\">",
"      Wu CF, Shee JJ, Lin WY, et al. Comparison between extracorporeal shock wave lithotripsy and semirigid ureterorenoscope with holmium:YAG laser lithotripsy for treating large proximal ureteral stones. J Urol 2004; 172:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/20\">",
"      Dretler SP. Ureteroscopy for proximal ureteral calculi: prevention of stone migration. J Endourol 2000; 14:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/21\">",
"      Sofer M, Watterson JD, Wollin TA, et al. Holmium:YAG laser lithotripsy for upper urinary tract calculi in 598 patients. J Urol 2002; 167:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/22\">",
"      Krambeck AE, Murat FJ, Gettman MT, et al. The evolution of ureteroscopy: a modern single-institution series. Mayo Clin Proc 2006; 81:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/23\">",
"      Schatloff O, Lindner U, Ramon J, Winkler HZ. Randomized trial of stone fragment active retrieval versus spontaneous passage during holmium laser lithotripsy for ureteral stones. J Urol 2010; 183:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/24\">",
"      Wang CJ, Huang SW, Chang CH. Randomized trial of NTrap for proximal ureteral stones. Urology 2011; 77:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/25\">",
"      Mugiya S, Ozono S, Nagata M, et al. Retrograde endoscopic management of ureteral stones more than 2 cm in size. Urology 2006; 67:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/26\">",
"      Hruza M, Schulze M, Teber D, et al. Laparoscopic techniques for removal of renal and ureteral calculi. J Endourol 2009; 23:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/27\">",
"      Singh V, Sinha RJ, Gupta DK, et al. Transperitoneal versus retroperitoneal laparoscopic ureterolithotomy: a prospective randomized comparison study. J Urol 2013; 189:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/28\">",
"      Teichman JM. Clinical practice. Acute renal colic from ureteral calculus. N Engl J Med 2004; 350:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/29\">",
"      Bierkens AF, Hendrikx AJ, De La Rosette JJ, et al. Treatment of mid- and lower ureteric calculi: extracorporeal shock-wave lithotripsy vs laser ureteroscopy. A comparison of costs, morbidity and effectiveness. Br J Urol 1998; 81:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/30\">",
"      Kourambas J, Delvecchio FC, Preminger GM. Low-power holmium laser for the management of urinary tract calculi, structures, and tumors. J Endourol 2001; 15:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/31\">",
"      Farsi HM, Mosli HA, Alzimaity M, et al. In situ extracorporeal shock wave lithotripsy for primary ureteric calculi. Urology 1994; 43:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/32\">",
"      Netto J&uacute;nior NR, Claro Jde A, Esteves SC, Andrade EF. Ureteroscopic stone removal in the distal ureter. Why change? J Urol 1997; 157:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/33\">",
"      Teh CL, Zhong P, Preminger GM. Laboratory and clinical assessment of pneumatically driven intracorporeal lithotripsy. J Endourol 1998; 12:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/34\">",
"      Arrabal-Polo MA, Arrabal-Mart&iacute;n M, Mij&aacute;n-Ortiz JL, et al. Treatment of ureteric lithiasis with retrograde ureteroscopy and holmium: YAG laser lithotripsy vs extracorporeal lithotripsy. BJU Int 2009; 104:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/35\">",
"      Harmon WJ, Sershon PD, Blute ML, et al. Ureteroscopy: current practice and long-term complications. J Urol 1997; 157:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/36\">",
"      Borboroglu PG, Amling CL, Schenkman NS, et al. Ureteral stenting after ureteroscopy for distal ureteral calculi: a multi-institutional prospective randomized controlled study assessing pain, outcomes and complications. J Urol 2001; 166:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/37\">",
"      Byrne RR, Auge BK, Kourambas J, et al. Routine ureteral stenting is not necessary after ureteroscopy and ureteropyeloscopy: a randomized trial. J Endourol 2002; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27079/abstract/38\">",
"      Graff J, Diederichs W, Schulze H. Long-term followup in 1,003 extracorporeal shock wave lithotripsy patients. J Urol 1988; 140:479.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7376 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27079=[""].join("\n");
var outline_f26_28_27079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16847592\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21125903\">",
"      OVERVIEW OF MANAGEMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21126001\">",
"      Emergency therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21126008\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21126027\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13011188\">",
"      - Ureteroscopy versus shock wave lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROXIMAL URETERAL CALCULI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Shock wave lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Flexible ureteroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Holmium laser lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Percutaneous antegrade approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Retroperitoneal laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MID-URETERAL CALCULI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DISTAL URETERAL STONES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECURRENT STONE FORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16847592\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30756?source=related_link\">",
"      Clinical significance of residual stone fragments following stone removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=related_link\">",
"      Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=related_link\">",
"      Options in the management of renal and ureteral stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=related_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_28_27080="Group C and group G streptococcal infection";
var content_f26_28_27080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Group C and group G streptococcal infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27080/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27080/contributors\">",
"     Arnold N Weinberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27080/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27080/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27080/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27080/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/28/27080/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 25, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcal infections are extremely common despite the overall susceptibility of these organisms to antibiotics, especially penicillin. While infections caused by the Lancefield group A streptococcus (GAS or Streptococcus pyogenes) have dominated the streptococcal medical literature, Lancefield groups C and G share many microbiologic and clinical characteristics with GAS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/1\">",
"     1",
"    </a>",
"    ]. (See related topic reviews on GAS).",
"   </p>",
"   <p>",
"    Work in the early 20th century described S. pyogenes as an exclusively human pathogen and detailed the frequency of carriers and the most characteristic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/2\">",
"     2",
"    </a>",
"    ]. The pioneering work of Rebecca Lancefield led to the identification of a number of groups of streptococci including A, C and G, producing hemolysis on sheep blood agar, exhibiting different biochemical properties and isolated from a variety of animal species [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/3\">",
"     3",
"    </a>",
"    ]. Classification methods based upon the Lancefield methodology were established soon thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among this diverse group, the group C and group G streptococci have assumed more important clinical roles. For a number of reasons, they can be considered together, separate from other members of the genus Streptococcus. Although less extensively studied, groups C and G streptococci are now appreciated to produce infections quite similar to GAS although they more commonly cause opportunistic and nosocomial infections than GAS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are widely distributed in the animal kingdom and are also part of the normal human flora.",
"     </li>",
"     <li>",
"      The microbiology is similar to GAS; they are primarily large colony, beta-hemolytic, and produce pyogenic and inflammatory reactions. On plates, colonies often resemble S. pyogenes, especially when susceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      They cause isolated exudative or common source epidemic pharyngitis and cellulitis indistinguishable clinically from GAS disease.",
"     </li>",
"     <li>",
"      Some strains contain fibrinolysins and streptolysins and infections can stimulate antistreptolysin O titers (ASO), similar to S. pyogenes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groups C and G streptococci are typical chaining cocci that are Gram positive, facultative anaerobes which produce small or large colonies on sheep blood agar. They are usually, but not exclusively, beta hemolytic. Unlike GAS, which are inhibited by 0.04",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    , the group C and G isolates are extremely variable in their bacitracin sensitivity, ranging from as few as 6 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/5\">",
"     5",
"    </a>",
"    ] to as many as 30 to 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/6\">",
"     6",
"    </a>",
"    ]. This variability should discourage the use of bacitracin as a screening step.",
"   </p>",
"   <p>",
"    By the mid-1930s Rebecca Lancefield and her colleagues developed the methodology that has led to modern day grouping of streptococci according to their acid extractable cell envelope carbohydrate or \"c substance.\" Not all streptococci can be grouped, but currently groups A through H and K through V are specific designations. Some groups and species are isolated from both humans and animals, others exclusively (as of today) from animals or from humans.",
"   </p>",
"   <p>",
"    Commercial methods for grouping streptococci are available to all diagnostic laboratories. The co-agglutination or latex agglutination kits for rapid identification of groups A, B, C, or G have become the standard for identifying the major beta hemolytic pathogens isolated from ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/7\">",
"     7",
"    </a>",
"    ]. The classification scheme for these organisms is confusing because groups A, C, and G can grow as small (&lt; 0.5 mm) or large colonies (&gt; 0.5 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/7-10\">",
"     7-10",
"    </a>",
"    ], and there is some overlap with group F organisms (Streptococcus intermedius group) although the latter are not beta hemolytic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/11\">",
"     11",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_algorithm graphicRef52456 \" href=\"UTD.htm?2/60/3023\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The vast majority of group C and G organisms that are pathogenic in humans, whether large or small colony type, produce a streptolysin. One study found that the chromosome of several group G streptococcal isolates that produced necrotizing skin infections had a homologue of the sag operon of GAS and that this encoded for streptolysin S [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/12\">",
"     12",
"    </a>",
"    ]. These group G streptococcal isolates caused an inflammatory skin lesion containing high bacterial counts in mice, while a mutant strain lacking streptolysin S did not.",
"   </p>",
"   <p>",
"    The small colony isolates are currently designated as Streptococcus milleri or Streptococcus anginosus group. Some of the large colony group C and G organisms are animal pathogens named after the species they most often infect. The major human pathogen in this group is S. dysgalactiae subsp. equisimilis, which can be Lancefield group C or G [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report described three blood culture isolates of streptococci which were positive for the Lancefield group A antigen but Voges-Proskauer (VP) negative and by 16S RNA analysis were identified as S. dysgalactiae subsp. equisimilis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/14\">",
"     14",
"    </a>",
"    ]. The affected patients had underlying diseases, and, in addition to bacteremia, one patient had cellulitis and one pharyngitis. Perhaps the Lancefield group designation will need revision as more 16S RNA analyses are undertaken.",
"   </p>",
"   <p>",
"    Other similarities and differences exist between GAS and the groups C and G streptococci:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group A streptococci (GAS) can be separated unequivocally using a positive pyrrolidonyl arylamidase hydrolysis test.",
"     </li>",
"     <li>",
"      S. dysgalactiae subsp. equisimilis, the group C or G species most frequently pathogenic for humans, contains approximately 20 percent of GAS virulence genes, including streptolysin O; in addition, approximately 50 percent of GAS virulence genes are expressed in at least one isolate of these organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A rise in ASO titers is well documented in infections by these organisms and can lead to confusion when seeking the etiology of a pharyngeal infection [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Post infectious non-suppurative complications might be expected based upon experience with GAS infections associated with elevated ASO titers. A few well documented cases of glomerulonephritis have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/18,19\">",
"       18,19",
"      </a>",
"      ], but it is possible that cases are overlooked by assuming an antecedent GAS infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=see_link\">",
"       \"Complications of streptococcal tonsillopharyngitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Protein T and M type proteins resembling those found in S. pyogenes have been described. Sophisticated genetic analyses suggest that M-like genes may be transferred between Lancefield groups A and G [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ECOLOGY AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the Lancefield group C and G streptococci occupy a number of ecological niches in humans and a variety of animals and birds. Despite the frequent presence in animals, only occasional reports of groups C and G infections in humans include information about exposures to animals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/22\">",
"     22",
"    </a>",
"    ]. Many group C and G streptococci are endogenous for humans [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/7,23-25\">",
"     7,23-25",
"    </a>",
"    ] and have been appreciated to be opportunistic pathogens in compromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ecology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many domestic animals, including horses, cattle, sheep, pigs, lambs and chickens are carriers of several species of group C or G streptococci. Active infections have been described in a number of animal hosts related to carriage of the organisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mastitis in cows",
"     </li>",
"     <li>",
"      \"Strangles\" in horses probably begins by invasion of paratracheal lymph nodes",
"     </li>",
"     <li>",
"      Guinea pigs are especially susceptible to infections with S. equi subsp. zooepidemicus (group C).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Humans are usual hosts for a number of large and small colony group C and G species that have been identified as part of the normal flora of the skin, oral cavity, nasopharynx, gastrointestinal tract, and vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/25\">",
"     25",
"    </a>",
"    ]. They also have been cultured from periumbilical specimens of healthy newborns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There was a hiatus of approximately thirty years between the first reports of infections due to other groupable beta hemolytic streptococci than GAS and a resurgence of interest in these pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The increased reporting of these organisms can be explained partially by the improved techniques for identification in the diagnostic microbiology laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the influence of underlying medical diseases and social conditions on the opportunistic expression of infections with these organisms also has been striking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/27,30\">",
"     27,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Frequent underlying characteristics of patients with groups C and G infection are [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/27,31\">",
"     27,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elderly and fragile",
"     </li>",
"     <li>",
"      Male sex (ratio of male to female cases is &gt;2:1)",
"     </li>",
"     <li>",
"      Underlying medical condition including cardiovascular disease, diabetes mellitus, cirrhosis, chronic alcoholism, bone and joint disease, and dermatologic processes",
"     </li>",
"     <li>",
"      Immunocompromised state including malignancy, immunosuppressive drugs, neutropenia, and acquired immunodeficiency syndrome (AIDS)",
"     </li>",
"     <li>",
"      Elective surgical procedures",
"     </li>",
"     <li>",
"      Animal or animal product exposure (however, animal product exposure is rarely indicated, perhaps because an adequate detailed history has not been obtained).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A ten-year survey from one hospital in Israel found that group G streptococcal bacteremia was more common than group A streptococcal bacteremia by 1999, accounting for 13 of 31,440 admissions compared to 0 of 18,783 in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/32\">",
"     32",
"    </a>",
"    ]. A presumed skin or soft tissue portal of entry was frequent, and the majority of patients were men over the age of 75 years.",
"   </p>",
"   <p>",
"    The majority of infections have been in or near areas of known colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/25,30\">",
"     25,30",
"    </a>",
"    ]. Polymicrobial abscesses and bacteremias are common probably reflecting breakdown of local host defense [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/25\">",
"     25",
"    </a>",
"    ]. Precision in determining the etiologic diagnosis of exudative pharyngitis has confirmed that cases due to S. pyogenes or to groups C or G organisms are indistinguishable clinically and epidemiologically; epidemic pharyngitis can be droplet or food associated regardless of the organism involved [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/17,33,34\">",
"     17,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both large and small colony group C and G streptococci cause a range of clinical infections. However, small colony organisms, which colonize the pharynx, have not been associated with pharyngitis compared to large colony organisms which produce endemic and epidemic exudative pharyngitis indistinguishable from that caused by GAS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/35\">",
"     35",
"    </a>",
"    ]. Small colony organisms are more likely to cause abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/25,36\">",
"     25,36",
"    </a>",
"    ]. Both colony types cause bacteremia, but large colony organisms have been associated more commonly with endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Large colony",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, typical exudative pharyngitis with fever and adenopathy indistinguishable from GAS tonsillopharyngitis can be caused by large colony group C and G organisms, especially S. dysgalactiae subsp. equisimilis. Both isolated cases and epidemic disease occur. In one study of 222 consecutive patients with pharyngitis in a pediatric practice, group G streptococcus was isolated in 56 children (25 percent) over an eight week period in one year with fewer isolates both before and after this time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/16\">",
"     16",
"    </a>",
"    ]. GAS was recovered from 91 (41 percent) in this same series. In another study of college students with exudative pharyngitis, group C S. dysgalactiae subsp. equisimilis was isolated from 11 percent of patients but not from patients with rhinovirus infection or controls without pharyngitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link\">",
"     \"Evaluation of acute pharyngitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These streptococci normally reside in small number in the pharynx, but like GAS they are found either in pure culture or as the predominant organism in clinical cases of pharyngitis. Precision in diagnosis, using either pyrrolidonyl arylamidase (PYR) hydrolysis to eliminate GAS or Lancefield grouping, has confirmed the relationship of these organisms to pharyngitis. In one study students who were not taking medication faithfully had increases in paired ASO titers, but no post infectious complications were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cellulitis and septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of cellulitis and septic arthritis are caused by other organisms than groups C or G streptococci. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .) However, among the manifestations of infection due to these organisms, these infections are common as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 37 patients with group G streptococcal isolates over a three year period, 32 percent had cellulitis and 16 percent septic arthritis or osteomyelitis compared to 8 percent with endocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In report of 94 episodes of group G streptococcal bacteremia, cellulitis was the source in 61 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/40\">",
"       40",
"      </a>",
"      ]. Approximately one-half of patients with cellulitis had an underlying skin lesion, mostly due to malignancy, surgery, or radiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both of these studies, all but 8 percent of patients had underlying predisposing medical conditions, most often malignancy or diabetes mellitus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with recurrent episodes of lower extremity cellulitis and no obvious portal of entry, anal colonization with group G streptococcus and possibly group A and other beta-hemolytic streptococci may constitute a reservoir for infection [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Septic arthritis, including involvement of multiple joints, is being reported with increasing frequency. In one study 23 cases of septic arthritis due to beta hemolytic streptococci were reviewed over 11 years; 40 percent were caused by GAS, and 30 percent each by group B and group G streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/42\">",
"     42",
"    </a>",
"    ]. Predisposing underlying conditions include rheumatoid, gouty, and traumatic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/43\">",
"     43",
"    </a>",
"    ]; prosthetic joint infection with these organisms has also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/44\">",
"     44",
"    </a>",
"    ]. Osteomyelitis can accompany septic arthritis. Results of therapy have varied from excellent, even with preservation of prosthetic joints, to poor outcomes in natural joints [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloodstream isolation of these organisms can occur, although they are less common causes of beta hemolytic streptococcal bacteremia than GAS or GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/40,46\">",
"     40,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42551?source=see_link\">",
"     \"Group A streptococcal (Streptococcus pyogenes) bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Group G streptococcal bacteremia can occur with or without an overt clinical focus. In two series with a total of 121 patients, 28 (23 percent) had a primary bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. When a source is identified, cellulitis is most common [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent bacteremia can occur (6 of 84 patients in one report), most often in patients with chronic lymphatic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/40\">",
"     40",
"    </a>",
"    ]. Two of the recurrences were with the same clone. This observation suggests that protective immunity was not acquired by the original infection, a finding that has also been noted in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the bacteremia is polymicrobial, the mix of organisms can be a clue to the portal of entry. When a focus of infection is not apparent, the source is usually assumed to be colonizing flora that enter following a transient breach of a normal barrier such as a degenerating polyp in the colon or an erosive vaginal lesion. A variety of underlying conditions also can predispose patients to invasion by normal flora. Subclinical or clinical malignant disease, diabetes and chronic alcoholism stand out as a major factors in cases of bacteremia. Echocardiography should be performed in all cases of bacteremia to exclude endocarditis. If a transthoracic echocardiogram is done and shows any abnormalities, a transesophageal echocardiogram usually is performed also. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports of both group C and G streptococcal endocarditis have appeared in the literature, and have often included review of existing published cases, which makes quantifying the incidence of endocarditis due to these bacteria difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/37,48\">",
"     37,48",
"    </a>",
"    ]. In one series of endocarditis cases, beta hemolytic streptococci accounted for fewer than five percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/49\">",
"     49",
"    </a>",
"    ]. Through the Emerging Infections Network of the Infectious Diseases Society of America, 31 cases of endocarditis caused by beta hemolytic streptococci were identified; GBS accounted for 21, GAS 5, and group G streptococcus only 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A presumptive or definite diagnosis of endocarditis can be determined from classic clinical clues, supporting laboratory studies and echocardiography. A focus that initiated the bacteremia preceding the development of endocarditis can occasionally be found, and distant suppurative complications may follow heart valve involvement. Although there are no distinctive clinical features to separate cases of endocarditis due to groups C and G streptococci from those caused by other organisms, there is a suggestion that complications of endocarditis, especially abscesses or emboli, are more common with these pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. However, many patients in these studies are immunocompromised hosts which may be as important a factor as the nature of the organism. TEE is more sensitive than TTE in detecting myocardial or annular abscesses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .) Endocarditis caused by small colony S. milleri group organisms is seldom seen, even in the presence of high grade bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of other infections have occasionally been reported to be caused by groups C and G streptococci. Cholangitis, cholecystitis and liver involvement are occasionally reported in association with obstructive biliary disease or as a consequence of bacteremia, usually in compromised hosts. Pneumonia, with or without empyema, is well documented and usually occurs secondary to antecedent viral URI followed by aspiration in patients burdened by chronic lung disease or other compromising conditions. Fever, pleuritic pain, pleural effusions and cavitation may complicate pneumonia, and bacteremia has been recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin and soft tissue infections similar to GAS infections include the entire spectrum from superficial impetigo, pyoderma, or erysipelas following vein harvest procedures, trauma, and secondary invasion of preexisting ulcers. Group C and G streptococci have also been implicated in cases of necrotizing fasciitis, myositis, and pyomyositis. Streptococcal toxic shock has complicated soft tissue infections caused by these organisms although not with the same frequency as GAS infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Small colony (S. anginosus group)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Local abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;A characteristic of the S. milleri group is their frequent association with abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/36\">",
"     36",
"    </a>",
"    ]. These organisms frequently colonize mucous membranes, and this accounts for their presence in dental, lung, brain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/56\">",
"     56",
"    </a>",
"    ], hepatic, pelvic, perinephric and subcutaneous abscesses. Often polymicrobial, these collections may spread to adjacent and to distant tissues and are frequently accompanied by mono- or polymicrobial bacteremia. If not clinically apparent by history, local findings or non-invasive radiographic techniques, an abscess should be strongly considered if these organisms are isolated from the blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the findings with large colony organisms, the majority of reported bacteremias with the small colony phenotype are associated with sites of primary suppurative disease in various organ systems, including respiratory, abdominal (including hepatic and peritoneal), head and neck, and soft tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/25\">",
"     25",
"    </a>",
"    ]. Many bacteremias emanate from local abscesses in liver, peritoneal, or pelvic areas. From normal residence on mucous membranes, these organisms can invade the circulation following local trauma, even without a clinically obvious focal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/36\">",
"     36",
"    </a>",
"    ]. Gastrointestinal ulceration and bleeding and premature rupture of membranes are examples of portals of entry.",
"   </p>",
"   <p>",
"    In one report, approximately half of the bacteremias were polymicrobial, including anaerobes and members of the Enterobacteriaceae family [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/36\">",
"     36",
"    </a>",
"    ]. Small foci of infection or malignancy were frequently the site of origin for polymicrobial bacteremias and support the observation that these organisms are locally present and contribute to mixed infection in areas that they ordinarily colonize [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, endocarditis is unusual with the small colony organisms. When endocarditis does occur, it is more common in patients with damaged or prosthetic heart valves than with normal, native valves. A number of studies have concluded that bacteremias due to the S. milleri group are more often associated with focal suppuration or abscesses then with endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/25,36\">",
"     25,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like with abscesses, many other infections caused by small colony group C or G streptococci occur in locations contiguous to areas of normal colonization. While pharyngitis is not caused by these organisms, invasion of sinuses, peritonsillar abscess, and facial cellulitis are recognized infections. Pleural or pneumonic infections usually follow aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]; peritonitis is a complication of bacteremic spread or bowel perforation; and other soft tissues, serosal surfaces, and bones may be sites of metastatic infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of an infection caused by group C or G streptococci is made by identification of the organism in culture. A provisional identification can be made from the beta hemolytic pattern on blood agar medium. However, as described above, confusion with GAS is common and an algorithm for the definitive identification of these streptococcal isolates should be followed (",
"    <a class=\"graphic graphic_algorithm graphicRef52456 \" href=\"UTD.htm?2/60/3023\">",
"     algorithm 1",
"    </a>",
"    ). Since these organisms are often part of the flora in a polymicrobial infection, it is important for the microbiology laboratory to identify all species in a specimen from a closed space or bacteremic process.",
"   </p>",
"   <p>",
"    When these organisms are isolated from the blood, especially in the absence of overt focal disease, an active search should be initiated for an abscess, endocarditis or a suppurative process in an obscure area. In cases of suppurative pharyngitis, only large colony beta hemolytic streptococci should be identified to Lancefield group since resident small colony streptococci are part of the pharyngeal flora and are not considered pathogens in exudative pharyngitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy may be administered to mitigate the clinical course of pharyngitis due to Group C and group G streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/60\">",
"     60",
"    </a>",
"    ]. Efficacy data are limited; one randomized trial of patients with non-GAS pharyngitis demonstrated only borderline efficacy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (vs placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/61\">",
"     61",
"    </a>",
"    ]. In general, five days of treatment is sufficient since acute rheumatic fever and post streptococcal glomerulonephritis are not complications of infection due to these organisms. The approach to antibiotic selection is as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most large and small colony types of group C and G streptococci are exquisitely susceptible to penicillin. In one study of the antimicrobial susceptibility of 646 beta hemolytic streptococcal isolates (17 percent group G and 6 percent group C), only 6 percent were resistant to one or more antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/62\">",
"     62",
"    </a>",
"    ]. Resistance primarily to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    was higher in the tertiary care center than in community hospitals, but even there, only 7 percent of 387 strains were resistant to erythromycin.",
"   </p>",
"   <p>",
"    Macrolide resistance (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ) among GAS isolates has been reported and may be related to selective pressure from their extensive use in individual communities or even countries; this effect can be reversed by a concerted effort in the community to limit macrolide use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For life-threatening infections (eg, meningitis, brain abscess, endocarditis) or in a severely compromised host [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27080/abstract/64\">",
"     64",
"    </a>",
"    ], minimum inhibitory concentration (MIC) determinations should be performed on the isolate. An aminoglycoside, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    (dose adjusted for renal insufficiency), should be administered for synergy in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (2 to 4 million units IV every four hours).",
"   </p>",
"   <p>",
"    In penicillin allergic patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    or a macrolide can be substituted. In areas where resistance to these agents is higher or for patients who are immunocompromised or have a severe infection,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (1 gm IV every 12 hours) should be considered.",
"   </p>",
"   <p>",
"    For polymicrobial infections additional therapy may be required for broad activity against additional pathogens. Drainage of abscesses is essential and can often be accomplished percutaneously, using ultrasound or computerized tomography in the radiology department.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/1\">",
"      Broyles LN, Van Beneden C, Beall B, et al. Population-based study of invasive disease due to beta-hemolytic streptococci of groups other than A and B. Clin Infect Dis 2009; 48:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/2\">",
"      Rammelkamp CH Jr. Epidemiology of streptococcal infections. Harvey Lect 1955- 1956; 51:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/3\">",
"      Lancefield RC. A SEROLOGICAL DIFFERENTIATION OF HUMAN AND OTHER GROUPS OF HEMOLYTIC STREPTOCOCCI. J Exp Med 1933; 57:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/4\">",
"      Sherman JM. THE STREPTOCOCCI. Bacteriol Rev 1937; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/5\">",
"      Pollock HM, Dahlgren BJ. Distribution of streptococcal groups in clinical specimens with evaluation of bacitracin screening. Appl Microbiol 1974; 27:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/6\">",
"      Stoner RA. Bacitracin and coagglutination for grouping of beta-hemolytic streptococci. J Clin Microbiol 1978; 7:463.",
"     </a>",
"    </li>",
"    <li>",
"     Facklam, RR, Washington, JA II. Streptococcus and related catalase-negative gram- positive cocci. In: Manual of Clinical Microbiology, 5th ed, Ballows, A, Hausler, WJ Jr, Hermann, KL et al (Eds), American Society for Microbiology, Washington, DC, 1991, p. 238.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/8\">",
"      Freney J, Bland S, Etienne J, et al. Description and evaluation of the semiautomated 4-hour rapid ID 32 Strep method for identification of streptococci and members of related genera. J Clin Microbiol 1992; 30:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/9\">",
"      Kirby R, Ruoff KL. Cost-effective, clinically relevant method for rapid identification of beta-hemolytic streptococci and enterococci. J Clin Microbiol 1995; 33:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/10\">",
"      Vandamme P, Pot B, Falsen E, et al. Taxonomic study of lancefield streptococcal groups C, G, and L (Streptococcus dysgalactiae) and proposal of S. dysgalactiae subsp. equisimilis subsp. nov. Int J Syst Bacteriol 1996; 46:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/11\">",
"      Kaufhold A, Ferrieri P. The microbiologic aspects, including diagnosis, of beta-hemolytic streptococcal and enterococcal infections. Infect Dis Clin North Am 1993; 7:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/12\">",
"      Humar D, Datta V, Bast DJ, et al. Streptolysin S and necrotising infections produced by group G streptococcus. Lancet 2002; 359:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/13\">",
"      Brandt CM, Spellerberg B. Human infections due to Streptococcus dysgalactiae subspecies equisimilis. Clin Infect Dis 2009; 49:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/14\">",
"      Brandt CM, Haase G, Schnitzler N, et al. Characterization of blood culture isolates of Streptococcus dysgalactiae subsp. equisimilis possessing Lancefield's group A antigen. J Clin Microbiol 1999; 37:4194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/15\">",
"      Davies MR, McMillan DJ, Beiko RG, et al. Virulence profiling of Streptococcus dysgalactiae subspecies equisimilis isolated from infected humans reveals 2 distinct genetic lineages that do not segregate with their phenotypes or propensity to cause diseases. Clin Infect Dis 2007; 44:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/16\">",
"      Gerber MA, Randolph MF, Martin NJ, et al. Community-wide outbreak of group G streptococcal pharyngitis. Pediatrics 1991; 87:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/17\">",
"      Turner JC, Hayden FG, Lobo MC, et al. Epidemiologic evidence for Lancefield group C beta-hemolytic streptococci as a cause of exudative pharyngitis in college students. J Clin Microbiol 1997; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/18\">",
"      Barnham M, Thornton TJ, Lange K. Nephritis caused by Streptococcus zooepidemicus (Lancefield group C). Lancet 1983; 1:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/19\">",
"      Gnann JW Jr, Gray BM, Griffin FM Jr, Dismukes WE. Acute glomerulonephritis following group G streptococcal infection. J Infect Dis 1987; 156:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/20\">",
"      Schnitzler N, Podbielski A, Baumgarten G, et al. M or M-like protein gene polymorphisms in human group G streptococci. J Clin Microbiol 1995; 33:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/21\">",
"      Sriprakash KS, Hartas J. Lateral genetic transfers between group A and G streptococci for M-like genes are ongoing. Microb Pathog 1996; 20:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/22\">",
"      Bradley SF, Gordon JJ, Baumgartner DD, et al. Group C streptococcal bacteremia: analysis of 88 cases. Rev Infect Dis 1991; 13:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/23\">",
"      Hare, R. Sources of hemolytic streptococcal infections of wounds in war and in civil life. Lancet 1940; 1:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/24\">",
"      Rolston KV. Group G streptococcal infections. Arch Intern Med 1986; 146:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/25\">",
"      Gossling J. Occurrence and pathogenicity of the Streptococcus milleri group. Rev Infect Dis 1988; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/26\">",
"      Vartian C, Lerner PI, Shlaes DM, Gopalakrishna KV. Infections due to Lancefield group G streptococci. Medicine (Baltimore) 1985; 64:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/27\">",
"      Skogberg K, Simonen H, Renkonen OV, Valtonen VV. Beta-haemolytic group A, B, C and G streptococcal septicaemia: a clinical study. Scand J Infect Dis 1988; 20:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/28\">",
"      Rantz, LA, Kirby, WMM. Hemolytic streptococcus bacteremia. N Engl J Med 1942; 227:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/29\">",
"      Feingold DS, Stagg NL, Kunz LJ. Extrarespiratory streptococcal infections. Importance of the various serologic groups. N Engl J Med 1966; 275:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/30\">",
"      Duma, RJ, Weinberg, AN, Medrek, JF, Kunz, LJ. Streptococcal Infections. Medicine 1969; 48:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/31\">",
"      Salata RA, Lerner PI, Shlaes DM, et al. Infections due to Lancefield group C streptococci. Medicine (Baltimore) 1989; 68:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/32\">",
"      Sylvetsky N, Raveh D, Schlesinger Y, et al. Bacteremia due to beta-hemolytic Streptococcus group G: increasing incidence and clinical characteristics of patients. Am J Med 2002; 112:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/33\">",
"      Hill HR, Caldwell GG, Wilson E, et al. Epidemic of pharyngitis due to streptococci of Lancefield group G. Lancet 1969; 2:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/34\">",
"      Cohen D, Ferne M, Rouach T, Bergner-Rabinowitz S. Food-borne outbreak of group G streptococcal sore throat in an Israeli military base. Epidemiol Infect 1987; 99:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/35\">",
"      Turner JC, Fox A, Fox K, et al. Role of group C beta-hemolytic streptococci in pharyngitis: epidemiologic study of clinical features associated with isolation of group C streptococci. J Clin Microbiol 1993; 31:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/36\">",
"      Bert F, Bariou-Lancelin M, Lambert-Zechovsky N. Clinical significance of bacteremia involving the \"Streptococcus milleri\" group: 51 cases and review. Clin Infect Dis 1998; 27:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/37\">",
"      Smyth EG, Pallett AP, Davidson RN. Group G streptococcal endocarditis: two case reports, a review of the literature and recommendations for treatment. J Infect 1988; 16:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/38\">",
"      McCue JD. Group G streptococcal pharyngitis. Analysis of an outbreak at a college. JAMA 1982; 248:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/39\">",
"      Liu CE, Jang TN, Wang FD, et al. Invasive group G streptococcal infections: a review of 37 cases. Zhonghua Yi Xue Za Zhi (Taipei) 1995; 56:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/40\">",
"      Cohen-Poradosu R, Jaffe J, Lavi D, et al. Group G streptococcal bacteremia in Jerusalem. Emerg Infect Dis 2004; 10:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/41\">",
"      Eriksson BK. Anal colonization of group G beta-hemolytic streptococci in relapsing erysipelas of the lower extremity. Clin Infect Dis 1999; 29:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/42\">",
"      Schattner A, Vosti KL. Bacterial arthritis due to beta-hemolytic streptococci of serogroups A, B, C, F, and G. Analysis of 23 cases and a review of the literature. Medicine (Baltimore) 1998; 77:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/43\">",
"      Ike RW. Septic arthritis due to group C streptococcus: report and review of the literature. J Rheumatol 1990; 17:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/44\">",
"      Gaunt PN, Seal DV. Group G streptococcal infection of joints and joint prostheses. J Infect 1986; 13:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/45\">",
"      Burkert T, Watanakunakorn C. Group G streptococcus septic arthritis and osteomyelitis: report and literature review. J Rheumatol 1991; 18:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/46\">",
"      Nielsen SV, Kolmos HJ. Bacteraemia due to different groups of beta-haemolytic streptococci: a two-year survey and presentation of a case of recurring infection due to Streptococcus \"equisimilis\". Infection 1993; 21:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/47\">",
"      Bisno AL, Gaviria JM. Murine model of recurrent group G streptococcal cellulitis: no evidence of protective immunity. Infect Immun 1997; 65:4926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/48\">",
"      Stein DS, Panwalker AP. Group C streptococcal endocarditis: case report and review of the literature. Infection 1985; 13:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/49\">",
"      Sandre RM, Shafran SD. Infective endocarditis: review of 135 cases over 9 years. Clin Infect Dis 1996; 22:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/50\">",
"      Baddour LM. Infective endocarditis caused by beta-hemolytic streptococci. The Infectious Diseases Society of America's Emerging Infections Network. Clin Infect Dis 1998; 26:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/51\">",
"      Raizes EG, Livingston MB, Farrar WE. Fatal cardiac tamponade in a young man with group C streptococcal endocarditis. Am J Med Sci 1987; 294:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/52\">",
"      Pollack BD, Belkin RN, Rubin DA, Moggio RA. Aortic annular abscess complicating prosthetic valve endocarditis with group G streptococcus: detection during life with transesophageal echocardiography. J Heart Valve Dis 1993; 2:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/53\">",
"      Dolinski SY, Jones PG, Zabransky RJ, Rasansky M. Group C streptococcal pleurisy and pneumonia: a fulminant case and review of the literature. Infection 1990; 18:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/54\">",
"      Keiser P, Campbell W. 'Toxic strep syndrome' associated with group C Streptococcus. Arch Intern Med 1992; 152:882, 884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/55\">",
"      Wagner JG, Schlievert PM, Assimacopoulos AP, et al. Acute group G streptococcal myositis associated with streptococcal toxic shock syndrome: case report and review. Clin Infect Dis 1996; 23:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/56\">",
"      Maniglia RJ, Roth T, Blumberg EA. Polymicrobial brain abscess in a patient infected with human immunodeficiency virus. Clin Infect Dis 1997; 24:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/57\">",
"      Ruoff KL, Kunz LJ, Ferraro MJ. Occurrence of Streptococcus milleri among beta-hemolytic streptococci isolated from clinical specimens. J Clin Microbiol 1985; 22:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/58\">",
"      Wong CA, Donald F, Macfarlane JT. Streptococcus milleri pulmonary disease: a review and clinical description of 25 patients. Thorax 1995; 50:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/59\">",
"      Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. Am J Med 2006; 119:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/60\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/61\">",
"      Petersen K, Phillips RS, Soukup J, et al. The effect of erythromycin on resolution of symptoms among adults with pharyngitis not caused by group A streptococcus. J Gen Intern Med 1997; 12:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/62\">",
"      Carroll KC, Monroe P, Cohen S, et al. Susceptibility of beta-hemolytic streptococci to nine antimicrobial agents among four medical centers in Salt Lake City, Utah, USA. Diagn Microbiol Infect Dis 1997; 27:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/63\">",
"      Sepp&auml;l&auml; H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27080/abstract/64\">",
"      Jacobs JA, de Krom MC, Kellens JT, Stobberingh EE. Meningitis and sepsis due to group G streptococcus. Eur J Clin Microbiol Infect Dis 1993; 12:224.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3172 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27080=[""].join("\n");
var outline_f26_28_27080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ECOLOGY AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ecology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Large colony",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cellulitis and septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Small colony (S. anginosus group)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Local abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3172\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3172|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?2/60/3023\" title=\"algorithm 1\">",
"      Lab identification of strep",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=related_link\">",
"      Complications of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=related_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42551?source=related_link\">",
"      Group A streptococcal (Streptococcus pyogenes) bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_28_27081="Cutaneous melanoma: Management of in transit metastases";
var content_f26_28_27081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cutaneous melanoma: Management of in transit metastases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27081/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27081/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27081/contributors\">",
"     Douglas Tyler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27081/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27081/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27081/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27081/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/28/27081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with primary cutaneous melanoma, the term \"locoregional metastases\" refers to local recurrences, in transit and satellite metastases, and regional lymph node metastases.",
"   </p>",
"   <p>",
"    In transit metastases develop within regional dermal and subdermal lymphatics prior to reaching the regional lymph nodes. The American Joint Committee on Cancer (AJCC) defines in transit metastases as any skin or subcutaneous metastases that are more than 2 cm from the primary lesion but are not beyond the regional nodal basin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/1\">",
"     1",
"    </a>",
"    ]. The 2010 tumor node metastasis (TNM) staging system (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ) considers in transit and satellite metastases to be a component of nodal (N) staging, assigning a separate N2c designation when they arise in the absence of nodal metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In transit metastases are differentiated from satellite lesions, which are skin or subcutaneous lesions within 2 cm of the primary tumor that are considered intralymphatic extensions of the primary mass. Despite this distinction, the tumor biology associated with satellite and in transit metastases is similar, and they are not considered as distinct entities for treatment or prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for both in transit metastases and satellite lesions is similar to that of patients with multiple nodal metastases. Patients with combined",
"    <span class=\"nowrap\">",
"     satellite/in",
"    </span>",
"    transit metastases and nodal metastases have a worse prognosis than either alone, and these patients are classified as N3.",
"   </p>",
"   <p>",
"    The clinical distinction between a local recurrence and in transit metastases is often difficult, and the definitions are somewhat arbitrary. For establishing clinical trial endpoints, a local recurrence is defined as regrowth within 2 cm of the surgical scar following definitive excision of a primary melanoma with appropriate surgical margins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/5\">",
"     5",
"    </a>",
"    ]. Nodules growing more than 2 cm from the excision scar are termed in transit metastases. In reality, these arbitrary definitions often have little bearing on management decisions.",
"   </p>",
"   <p>",
"    The clinical presentation, evaluation, and management of patients with in transit metastases will be reviewed here. Local recurrences and nodal metastases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34007?source=see_link\">",
"     \"Cutaneous melanoma: Management of local recurrence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma in transit metastases typically appear as erythematous nodules ranging in size from 0.2 to 2 cm that may or may not be pigmented. Occasionally, the lesions are flat and pigmented.",
"   </p>",
"   <p>",
"    Although in transit metastases typically are located between the primary site and the regional nodes, they may extend in a direction opposite to that of the closest regional nodal basin in patients with extensive disease. This manifestation presumably reflects tumor blockage of lymphatic channels and altered patterns of lymphatic flow. Uncontrolled tumor growth can result in coalescence of lesions and tumor ulceration.",
"   </p>",
"   <p>",
"    For patients who present with in transit metastases, a careful assessment is necessary to determine whether disseminated disease is present, and the extent of such disease. The role of imaging modalities is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link&amp;anchor=H5#H5\">",
"     \"Staging work-up and surveillance after treatment of melanoma\", section on 'Clinical stage III and local recurrence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15450?source=see_link\">",
"     \"Imaging studies in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors at the time of initial presentation with cutaneous melanoma have been associated with an increased risk of in transit metastases. These include more advanced stage of the primary tumor (including greater thickness and the presence of ulceration), location of the tumor, and age greater than 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Primary tumor stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing in transit metastases is directly related to the stage of the primary melanoma. In multiple retrospective series of patients with clinical stage I or II disease (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ), the incidence is between 2.5 and 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/6-13\">",
"     6-13",
"    </a>",
"    ]. The risk is higher with more advanced local lesions and if there is lymphatic invasion in the primary tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The median time to recurrence for patients who develop in transit metastases ranges from 13 to 16 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]. If all regional relapses (local recurrence, in transit and nodal metastases) are considered, 70 to 80 percent will develop within three years after treatment of the primary lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nodal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing in transit metastases is greater in patients with regional nodal involvement, and the risk is proportional to the number of involved nodes. As an example, in one series the risk of in transit metastases in patients with one versus three or more positive nodes was 11 and 31 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anatomic site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of in transit metastases is also influenced by the anatomic site of the primary melanoma, and in transit metastases are especially common for lower extremity lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/6,11,14\">",
"     6,11,14",
"    </a>",
"    ]. In a review of 1000 patients with cutaneous melanoma, the following incidences of in transit metastases were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Head and neck &ndash; 5 percent",
"     </li>",
"     <li>",
"      Upper extremity &ndash; 8 percent",
"     </li>",
"     <li>",
"      Trunk &ndash; 9 percent",
"     </li>",
"     <li>",
"      Lower extremity &ndash; 19 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Influence of node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between regional lymph node dissection and the subsequent development of in transit metastases was an area of controversy, with some initial results suggesting that surgery can disrupt the lymphatic channels and increase the risk of subsequent in transit metastases. This issue is of particular concern with the widespread use of sentinel lymph node biopsy (SLNB).",
"   </p>",
"   <p>",
"    A possible relationship was suggested by an analysis of relapse patterns in a series of 1000 patients, in which the incidence of in transit metastases was greater in patients with node-positive disease who had undergone elective node dissection (ELND) rather than in those managed with a therapeutic node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/11\">",
"     11",
"    </a>",
"    ]. Other small observational studies in patients undergoing sentinel lymph node biopsy (SLNB) also observed that the incidence of in transit metastases was increased [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, two large observational studies and preliminary results from a randomized trial provide strong evidence that lymphatic disruption from surgical management of the regional lymphatics is not associated with an increased risk of in transit metastases or local recurrences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective series of 4412 patients with stage I or II melanoma, the incidence of in transit metastases was significantly higher in patients undergoing a wide local excision (WLE) plus ELND (6.6 versus 3.4 and 3.6 percent for WLE without and with SLNB, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/21\">",
"       21",
"      </a>",
"      ]. However, the higher rate of such metastases in patients undergoing ELND could be explained by differences in the patient characteristics, with those undergoing ELND having more high-risk features at presentation.",
"     </li>",
"     <li>",
"      In a study from M. D. Anderson of 1395 patients with extremity melanoma who underwent lymphatic mapping and sentinel lymph node biopsy, 6.5 percent developed in-transit recurrence at a mean follow-up of 3.5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/6\">",
"       6",
"      </a>",
"      ]. In 71 percent of these patients, the in-transit disease was the only site of recurrence.",
"     </li>",
"     <li>",
"      The Multicenter Selective Lymphadenectomy Trial (MSLT-I) randomly assigned patients with intermediate thickness melanoma to observation or lymphatic mapping and SLNB [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/22\">",
"       22",
"      </a>",
"      ]. In published results of a planned interim analysis based upon 1269 cases, there was no difference in the rate of local recurrence or in transit metastases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of in transit metastases may be performed with either curative or palliative intent. The principal approaches that have been used include surgical excision, isolated limb perfusion (ILP), isolated limb infusion, and intralesional therapy using a variety of agents. Other approaches that have had more limited success include systemic chemotherapy, biochemotherapy, immunotherapy, and radiation therapy (RT). Several novel approaches that are under development (eg, photodynamic therapy, gene therapy, laser ablation) are not addressed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of single or multiple in transit metastases is the treatment of choice when technically feasible with an acceptable level of morbidity. In cases where surgical resection is not possible, leaving existing disease in place may be useful to assess the effectiveness of alternative regional chemotherapy approaches. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Isolated limb perfusion or infusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although the majority of patients will have evidence of disseminated disease, a subset of those without distant metastases enjoy long-term relapse-free survival following surgery with a curative intent. This is illustrated by the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 648 patients with locoregionally recurrent melanoma at first relapse who underwent complete surgical resection, 124 (19 percent) had not relapsed, at a median follow-up of eight years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/16\">",
"       16",
"      </a>",
"      ]. The incidence rates for subsequent local recurrence, lymph node disease, and systemic metastases were 45, 34, and 17 percent respectively. Truncal primary tumor location and shorter disease-free intervals were associated with poorer outcomes following locoregional disease recurrence.",
"     </li>",
"     <li>",
"      Two separate series of 41 and 29 patients who underwent major amputation for advanced locoregional melanoma report 29 and 30 percent long-term relapse-free survival rates, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even if distant metastases are present, locoregional disease control is an important issue for quality of life because of pain and wound complications from ulcerating tumors. Surgery may be indicated in an effort to reduce or delay the morbidity (eg, bleeding, ulceration, pain) associated with progression of in transit disease.",
"   </p>",
"   <p>",
"    Sound clinical judgment is needed to assess the feasibility of resection for in transit melanoma metastases. Most patients who undergo resection will subsequently relapse, usually with additional in transit metastases. In most patients, the morbidity associated with excision of a few in transit metastases every 6 to 18 months is acceptable. However, an increased frequency of in transit melanoma relapses or a greater number of in transit nodules suggests that alternative regional or systemic treatments should be considered.",
"   </p>",
"   <p>",
"    The surgical principles for treating in transit lesions differ from those with a primary melanoma. A histologically negative margin is adequate, and the wider margins that are used to treat primary melanomas are not indicated. Depending upon the size of the metastases and the proximity to the original excision, the surgical defect may not be amenable to primary closure and may require skin grafting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Positive resection margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the goal of resection is to achieve histologically negative margins, microscopically positive margins are sometimes identified in the resection specimen. This does not necessarily mean that melanoma cells were left behind in the excision bed. Subcutaneous fat is loose tissue that is easily brushed aside during the process of inking the specimen, and the ink may have been inadvertently applied to the pseudocapsule of a completely excised in transit metastases.",
"   </p>",
"   <p>",
"    In this situation, the benefit of reresection to achieve negative margins as defined by the pathologist must be balanced against the morbidity of the procedure. Since the vast majority of these patients harbor additional occult metastases in regional lymphatic channels, the value of reresection to clear surgical margins is very limited.",
"   </p>",
"   <p>",
"    A reasonable alternative is to observe carefully and resect any recurrence that subsequently develops as a result of truly incomplete resection of in transit melanoma metastases. There are no data that directly compare outcomes following reresection versus observation for management of histologically positive margins in this situation. Thus, for patients with microscopically but not grossly positive margins resulting from in transit metastasectomy, we recommend reresection to clear margins only in those with the most favorable tumor biology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     SLN biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consideration should be given to performing lymphatic mapping and a sentinel lymph node (SLN) biopsy in patients with small volume in transit disease. The identification of regional lymph node involvement may provide important information that alters treatment recommendations with regard to surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic therapy.",
"   </p>",
"   <p>",
"    Lymphatic mapping and SLN biopsy can be performed even in patients who had a previous SLN biopsy and can be useful in determining the extent of surgery. There is no consensus about the utilization of SLN biopsy in this setting. Moreover, the technique, while similar to that described for patients with primary melanoma, is not standardized (eg, how many in transit metastases to inject, whether or not to inject the primary lesion or in transit metastases or both).",
"   </p>",
"   <p>",
"    The results with this approach are illustrated by a series of 30 patients with isolated local recurrence or in transit disease, in which 14 (47 percent) had a positive SLN biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/25\">",
"     25",
"    </a>",
"    ]. On completion node dissection, approximately one-third had additional positive nonsentinel lymph nodes. None of the patients with tumor-negative SLNs developed a recurrence in the dissected basin. Although follow-up was relatively short, no difference in overall survival between the tumor-positive and tumor-negative patient groups was observed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\", section on 'Sentinel lymph node biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34007?source=see_link\">",
"     \"Cutaneous melanoma: Management of local recurrence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with one or two small in transit lesions have several treatment options, especially if their disease is surgically resectable. In this setting, the additional information from a SLN biopsy may be helpful in determining the optimal treatment. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Isolated limb perfusion or infusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The role of SLN biopsy in altering clinical management is less clear in patients with three or more lesions. Generally, such patients are better managed with regional chemotherapy treatment, and therefore we generally do not recommend SLN biopsy in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Isolated limb perfusion or infusion",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated limb perfusion (ILP) involves surgical isolation of the vascular inflow and outflow of an extremity to separate the circulation of the affected limb from that of the remainder of the body (",
"    <a class=\"graphic graphic_figure graphicRef65340 \" href=\"UTD.htm?17/9/17558\">",
"     figure 1",
"    </a>",
"    ). Thus, high concentrations of drugs can be circulated locally without exposing the rest of the body to the same level of toxicity. By excluding the liver and kidney from the perfusion circuit, drug metabolism is minimized, thus leading to sustained high concentrations of drug in the perfused limb [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The isolated extremity is usually subjected to mild hyperthermia (eg 40&ordm;C) to improve antitumor effect without subjecting the entire body to the risks of hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/27\">",
"     27",
"    </a>",
"    ]. Hyperthermia does increase the regional toxicity of ILP, particularly with temperatures over 40&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/28\">",
"     28",
"    </a>",
"    ]. Although hyperthermic ILP increases response rates compared with historic controls, there are no randomized trials to indicate whether this affects survival [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/26,29-32\">",
"     26,29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial studies with ILP used nitrogen mustard and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    in patients with locally advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/29\">",
"     29",
"    </a>",
"    ]. Subsequent studies evaluated tumor necrosis factor alpha (TNFa), which is known to induce tumor necrosis and acts synergistically with chemotherapy agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/27,33,34\">",
"     27,33,34",
"    </a>",
"    ]. However, a randomized trial has not observed any benefit from the addition of TNF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/35\">",
"     35",
"    </a>",
"    ]. TNFa is not available in the United States.",
"   </p>",
"   <p>",
"    Hyperthermic ILP is performed under general anesthesia. Mild systemic hyperthermia produces vasodilatation so that sympathetic blockade is not needed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/36\">",
"     36",
"    </a>",
"    ]. Target tissue temperature generally ranges between 38.5&ordm;C and 40&ordm;C, and is monitored by thermistors that are placed in several areas of the extremity. Wrapping of the extremity in heating blankets reduces the time required to reach the target temperature once perfusion is initiated.",
"   </p>",
"   <p>",
"    ILP of the lower extremities is most commonly performed via cannulation of the external iliac vessels; the axillary vessels are used in the arm. However, ILP can be performed via the femoral or popliteal vessels in the lower extremity, and via the brachial vessels in the arm in certain clinical situations. The vessels are cannulated and connected to the inflow and outflow lines of an extracorporeal bypass circuit identical to that used in cardiac surgery.",
"   </p>",
"   <p>",
"    Vascular isolation of the extremity is needed to avoid leakage of perfusate into the systemic circulation and of systemic blood into the perfusion circuit. A tourniquet is applied around the root of the extremity to occlude superficial veins that could communicate between the limb circuit and the remainder of the body. The integrity of the ILP circuit can be assessed by examination of the body under a Wood's lamp after injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    . Alternatively, radiolabeled 131-I human serum albumin or 99-Tc labeled red blood cells may be used during ILP for continuous intraoperative leak monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For ILP using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    alone, the dose is generally based upon the volume of the extremity (10",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    limb volume for lower extremity and 13",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    limb volume for upper extremity) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/39\">",
"     39",
"    </a>",
"    ]. The optimal duration of perfusion has not been studied critically, but most surgeons perfuse for 60 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermic ILP is effective, but time and resource consuming as well as toxic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/40\">",
"     40",
"    </a>",
"    ]. Simpler and less morbid techniques have been developed to achieve high regional chemotherapy concentrations.",
"   </p>",
"   <p>",
"    An alternative type of regional chemotherapy treatment for melanoma that is gaining popularity is called normothermic isolated limb infusion (ILI) (",
"    <a class=\"graphic graphic_figure graphicRef65340 \" href=\"UTD.htm?17/9/17558\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. With this form of regional therapy, the artery and vein of an extremity are accessed percutaneously using high flow catheters, and a pneumatic tourniquet is used proximally to isolate the extremity. ILI differs from ILP in that ILI circulates blood in an isolated extremity at a much slower rate than ILP and for only 30 minutes. During ILI the extremity is hypoxic, which leads to marked acidosis. In contrast, with hyperthermic ILP, the pump oxygenator maintains the oxygenation and normal",
"    <span class=\"nowrap\">",
"     acid/base",
"    </span>",
"    status of the extremity.",
"   </p>",
"   <p>",
"    Two large series have been reported using ILI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Sydney Melanoma Unit used",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      in conjunction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"       dactinomycin",
"      </a>",
"      in a series of 185 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/41\">",
"       41",
"      </a>",
"      ]. This series included 86 patients (46 percent) age &ge;75 years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The overall response rate was 84 percent, including 38 percent complete and 46 percent partial responses. The median response duration was 13 months for all patients and 22 months for those with a complete response, and the procedure was equally effective and safe in the elderly patients. In appropriately selected patients, repeat ILI was feasible in patients with progressive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of this database, toxicity was grade III (erythema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      edema, with blistering) and grade IV (extensive epidermolysis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      obvious damage to deep tissues) in 39 and 3 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/46\">",
"       46",
"      </a>",
"      ]. No grade V toxicity (tissue damage severe enough to require amputation) was observed.",
"     </li>",
"     <li>",
"      Another analysis from the Sydney Melanoma Unit identified 14 of 235 patients in whom amputation ultimately was required [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/47\">",
"       47",
"      </a>",
"      ]. The reasons for amputation were generally to relieve symptoms due to progressive, infiltrative disease (bleeding, ulceration, necrosis, pain).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combined report from eight centers in the United States observed a somewhat lower response rate in 157 patients who were treated with ILI [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/48\">",
"       48",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"       Dactinomycin",
"      </a>",
"      was added to the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      regimen in 93 percent of infusions. The overall response rate was 64 percent, including 31 percent complete responses, in the 128 evaluable patients. Grade 3 or greater toxicity was observed in 36 percent of cases, and one patient required an amputation because of toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     Melphalan",
"    </a>",
"    remains the standard drug for ILI as well as ILP because of its rapid uptake by cells and because its mechanism of action is independent of the cell cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/49-53\">",
"     49-53",
"    </a>",
"    ]. Other agents that have been utilized include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Perfusion versus infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that compare hyperthermic ILP with ILI. However, the available evidence suggests that ILP is associated with a higher response rate that ILI, although it causes more severe toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/43,48,54\">",
"     43,48,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a combined analysis of the experience from the Sydney Melanoma Unit, Duke, and the United States multicenter study, the overall response rate was higher with ILP than with ILI (79 percent in 294 patients versus 64 percent in 313 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/48\">",
"     48",
"    </a>",
"    ]. The overall incidence of grade 3 or greater toxicity was similar (29 versus 33 percent), but ILP resulted in more grade 5 toxicity (2.0 versus 0.3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Clinical applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary use of ILP or ILI has been to treat unresectable in transit local-regional disease (",
"    <a class=\"graphic graphic_picture graphicRef51740 \" href=\"UTD.htm?8/42/8869\">",
"     picture 1",
"    </a>",
"    ). ILP has also been evaluated used as an adjuvant following resection of in transit metastases or a high-risk primary melanoma. Lymphatic mapping and SLN biopsy may be a useful adjunct in planning treatment when regional chemotherapy is being considered. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'SLN biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1579472546\">",
"    <span class=\"h4\">",
"     Unresectable in transit metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have shown that hyperthermic ILP or ILI can be an effective treatment for patients with unresectable melanoma that is confined to an extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/28,29,55-61\">",
"     28,29,55-61",
"    </a>",
"    ]. These approaches may also be used in carefully selected patients with stage IV melanoma, where there is a limited burden of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/62\">",
"     62",
"    </a>",
"    ]. The following reports illustrate the range of results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 120 patients with advanced limb melanoma undergoing mild hyperthermic or normothermic ILP with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      , the objective and complete response rates were 79 and 54 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/55\">",
"       55",
"      </a>",
"      ]. In a report of 42 patients with lesions in the lower limb, a double perfusion schedule using the same ILP regimen gave higher objective and complete response rates (90 and 76 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/56\">",
"       56",
"      </a>",
"      ]. However, regional toxicity and morbidity were worse in patients treated with the double perfusion schedule, and there were no differences in limb control rates or survival.",
"     </li>",
"     <li>",
"      In another study of 114 patients with locally recurrent or metastatic limb melanoma, hyperthermic ILP with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      resulted in a complete and partial response in 81 and 14 patients, respectively (73 and 13 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/61\">",
"       61",
"      </a>",
"      ]. Complete response was maintained in 37 of 81 cases without further treatment (median follow-up, 33 months, range, 8 to 112 months).",
"     </li>",
"     <li>",
"      The addition of TNFa to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      does not appear to add benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/35,55,58,63\">",
"       35,55,58,63",
"      </a>",
"      ]. This was illustrated by a phase III trial in which patients with advanced extremity melanoma were randomly assigned to ILP with melphalan alone or melphalan plus TNFa [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/35\">",
"       35",
"      </a>",
"      ]. The trial was closed prematurely when an interim analysis showed no benefit from the addition of TNFa. The final analysis showed no significant improvement in the response rate with TNFa plus melphalan (69 versus 64 percent, with melphalan alone), and an increased number of grade 4 adverse events (11 of 65 versus 3 of 64). While supported by a large single institution experience, it is still believed to be beneficial by European centers for individuals with bulky, high volume disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although preliminary studies suggested that local control was improved with low doses of IFNa preoperatively and in the perfusate with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      and TNFa [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/31,59,63\">",
"       31,59,63",
"      </a>",
"      ], these results were not confirmed in two randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/58,60\">",
"       58,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although ILP with TNF plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      does not appear to be superior to melphalan alone, two series suggest that retreatment with TNF plus melphalan is effective in patients who had failed ILP with melphalan alone [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. TNFa is not available in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no randomized trials that compare hyperthermic ILP or ILI with surgical excision of in transit metastases or systemic therapy. As mentioned above, surgical excision is the treatment of choice when feasible, with",
"    <span class=\"nowrap\">",
"     ILP/ILI",
"    </span>",
"    reserved for unresectable recurrences. Some unresectable recurrences may be converted to resectable following a response to",
"    <span class=\"nowrap\">",
"     ILP/ILI",
"    </span>",
"    therapy.",
"   </p>",
"   <p>",
"    Responses occur gradually, and the maximal tumor regression is usually present by three months. Patients who have a partial response at reassessment can undergo resection if the disease is deemed resectable or undergo a repeat regional chemotherapy treatment. Options for patients who progress include alternative regional chemotherapy regimens or systemic therapy.",
"   </p>",
"   <p>",
"    Adjuvant systemic therapy may be considered for patients who achieve a complete response with regional chemotherapy alone or with regional chemotherapy followed by surgery. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Adjuvant systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1579472656\">",
"    <span class=\"h4\">",
"     Resected in transit recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although patients who undergo resection for in transit recurrent melanoma in the extremity are at high risk for additional metastases, adjuvant regional chemotherapy is not routinely utilized after resection of an initial in transit recurrence. A Swedish trial randomly assigned 69 patients with resected melanoma recurrences to excision alone or surgery followed by hyperthermic ILP using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/66\">",
"     66",
"    </a>",
"    ]. ILP decreased the incidence of local recurrences (70 versus 83 percent without ILP) and was associated with a better three-year disease-free survival (33 versus 17 percent). However, overall survival was not significantly improved (55 versus 45 percent).",
"   </p>",
"   <p>",
"    Although we may consider adjuvant regional chemotherapy for patients with multiple recurrences who have had their most recent recurrence completely resected and continue to have negative regional lymph nodes, our preference is to limit regional therapies to those patients in whom in transit metastases cannot be fully resected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1579472671\">",
"    <span class=\"h4\">",
"     High-risk primary melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three randomized trials have evaluated adjuvant ILP in patients after resection of a primary high-risk melanoma. Two relatively small trials each showed a decreased incidence of local recurrence and suggested that there was an associated survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/12,31,67\">",
"     12,31,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a much larger European trial randomly assigned 832 patients with stage II resected melanoma to excision alone or surgery followed by hyperthermic ILP with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27081/abstract/12\">",
"     12",
"    </a>",
"    ]. At a follow-up of six years, adjuvant ILP was associated with a significantly lower incidence of regional recurrence (2.5 versus 9.9 percent without ILP), but there was no improvement in overall survival.",
"   </p>",
"   <p>",
"    Regional chemotherapy treatments are not recommended for patients in the adjuvant setting after resection of high risk primary tumors. In the absence of a survival benefit, the morbidity of the procedure is felt to outweigh the potential benefit of improved locoregional control. However, an occasional patient may present with a large primary tumor, for which resection would require extensive disfigurement. Regional chemotherapy may sometimes be utilized to downsize these tumors prior to definitive resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is used infrequently for in transit metastases, and is limited to situations in which disease is too extensive for surgical excision and ILP is either not possible or ineffective. RT may provide palliative benefit and occasionally, prolonged regional control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=see_link\">",
"     \"Role of radiation therapy in the management of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Intralesional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional injection of various agents has been used to treat melanoma lesions in the skin. These reports have included patients with in transit metastases, local recurrences, and skin metastases. The approach has largely been limited to patients with one or a very limited number of lesions.",
"   </p>",
"   <p>",
"    The use of intralesional therapy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34007?source=see_link&amp;anchor=H15#H15\">",
"     \"Cutaneous melanoma: Management of local recurrence\", section on 'Intralesional therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adjuvant systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While",
"    <span class=\"nowrap\">",
"     satellite/in",
"    </span>",
"    transit metastases and nodal metastases both appear to be evidence of micrometastasis through the lymphatics that drain the primary melanoma, there may be important molecular differences that direct the cells toward the skin versus the nodes. Whether such potential differences influence therapy is currently uncertain.",
"   </p>",
"   <p>",
"    In patients with positive regional lymph nodes, adjuvant high-dose interferon alfa (IFNa) is recommended following surgical resection of the regional lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized clinical trials are not available to address the value of adjuvant therapy in patients who are rendered disease-free following treatment of in transit metastases and are clinically or pathologically node negative. Although there are no data in this clinical setting, adjuvant IFNa should be considered since the risk of recurrence in these patients is similar to that of patients with lymph node involvement studied in the intergroup adjuvant studies. Enrollment in clinical trials is also a very important option for this patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapy may be useful for patients who are not candidates for therapy specifically directed against the regional disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"     \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=see_link\">",
"     \"Cytotoxic chemotherapy for metastatic melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"     \"Molecularly targeted therapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic therapy of melanoma is discussed in detail elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma satellite lesions and in transit metastases are manifestations of lymphatic tumor spread. Because their tumor biology and prognosis are similar, they are grouped together in the TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In approximately one-third of patients, aggressive treatment may be associated with prolonged survival when disease is limited to the extremity and there is no evidence of other metastases. Management of in transit disease requires a multidisciplinary approach that considers each patient's unique situation and access to surgical expertise, possible limb perfusion options, and clinical trials. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with in transit metastases, careful assessment is necessary to determine whether disseminated disease is present and the extent of such disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link&amp;anchor=H5#H5\">",
"       \"Staging work-up and surveillance after treatment of melanoma\", section on 'Clinical stage III and local recurrence'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15450?source=see_link\">",
"       \"Imaging studies in melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with one or two resectable in transit metastases but without other evidence of disease, we recommend surgical resection of all disease with curative intent (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose disease is limited to in transit metastases and who undergo a complete resection of all disease, adjuvant therapy with interferon alfa (IFNa) may be considered. Performing a sentinel lymph node biopsy at the time of excision may help guide this decision making process. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adjuvant systemic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"       \"Adjuvant immunotherapy for melanoma\"",
"      </a>",
"      .) When disseminated metastases are present, locoregional treatment with surgery may nevertheless be indicated in an effort to reduce or delay the morbidity (eg, bleeding, ulceration, pain) associated with progression of in transit disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For carefully selected patients with disseminated disease, but with a limited number of in transit metastases, we suggest surgical resection of the in transit metastases to prevent the development of locally symptomatic disease, as well as systemic therapy to treat other areas of disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=see_link\">",
"       \"Cytotoxic chemotherapy for metastatic melanoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with unresectable disease of the extremities, recurrent in transit disease of the extremity, or with three or more lesions, but with minimal or no systemic disease, we suggest isolated limb perfusion or limb infusion with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      if there is access to a center with adequate expertise in this technique (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Isolated limb perfusion or infusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For rare patients with unresectable disease in whom isolated limb perfusion or isolated limb infusion are either not available or not appropriate, we suggest palliative treatment with radiation therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical applications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=see_link\">",
"       \"Role of radiation therapy in the management of melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Melanoma of the Skin. In: American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.325.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/2\">",
"      Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/3\">",
"      Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997; 15:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/4\">",
"      Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/5\">",
"      Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/6\">",
"      Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005; 12:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/7\">",
"      Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 1999; 6:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/8\">",
"      Roses DF, Harris MN, Rigel D, et al. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983; 198:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/9\">",
"      McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988; 166:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/10\">",
"      Cascinelli N, Bufalino R, Marolda R, et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986; 12:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/11\">",
"      Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989; 124:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/12\">",
"      Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16:2906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/13\">",
"      Kretschmer L, Beckmann I, Thoms KM, et al. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma. Ann Surg Oncol 2006; 13:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/14\">",
"      Wong JH, Cagle LA, Kopald KH, et al. Natural history and selective management of in transit melanoma. J Surg Oncol 1990; 44:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/15\">",
"      Crowley NJ, Seigler HF. Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 1992; 127:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/16\">",
"      Dong XD, Tyler D, Johnson JL, et al. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 2000; 88:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/17\">",
"      Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/18\">",
"      Estourgie SH, Nieweg OE, Vald&eacute;s Olmos RA, et al. Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years. Ann Surg Oncol 2003; 10:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/19\">",
"      Thomas JM, Clark MA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol 2004; 30:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/20\">",
"      Estourgie SH, Nieweg OE, Kroon BB. High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg 2004; 91:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/21\">",
"      Kang JC, Wanek LA, Essner R, et al. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol 2005; 23:4764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/22\">",
"      Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/23\">",
"      Jaques DP, Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989; 169:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/24\">",
"      Ebskov LB. Major amputation for malignant melanoma: an epidemiological study. J Surg Oncol 1993; 52:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/25\">",
"      Yao KA, Hsueh EC, Essner R, et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg 2003; 238:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/26\">",
"      Minor DR, Allen RE, Alberts D, et al. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985; 55:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/27\">",
"      Omlor G, Gross G, Ecker KW, et al. Optimization of isolated hyperthermic limb perfusion. World J Surg 1992; 16:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/28\">",
"      Klaase JM, Kroon BB, van Geel BN, et al. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 1994; 167:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/29\">",
"      Krementz ET, Carter RD, Sutherland CM, et al. Regional chemotherapy for melanoma. A 35-year experience. Ann Surg 1994; 220:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/30\">",
"      Stehlin JS, Giovanella BC, de Ipolyi PD, et al. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975; 140:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/31\">",
"      Ghussen F, Nagel K, Groth W, et al. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 1984; 200:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/32\">",
"      Skene AI, Bulman AS, Williams TR, et al. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990; 77:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/33\">",
"      Miller RC, Richards M, Baird C, et al. Interaction of hyperthermia and chemotherapy agents; cell lethality and oncogenic potential. Int J Hyperthermia 1994; 10:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/34\">",
"      Alexander HR Jr, Fraker DL, Bartlett DL, et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 2010; 28:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/35\">",
"      Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24:4196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/36\">",
"      Hynson JM, Katz JA, Kinder E, Allen RE. Sympathetic blockade does not enhance tissue warming during isolated heated limb perfusion. Anesth Analg 1997; 85:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/37\">",
"      Klaase JM, Kroon BB, van Geel AN, et al. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993; 80:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/38\">",
"      Barker WC, Andrich MP, Alexander HR, Fraker DL. Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med 1995; 22:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/39\">",
"      Cheng TY, Grubbs E, Abdul-Wahab O, et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg 2003; 186:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/40\">",
"      Vrouenraets BC, in't Veld GJ, Nieweg OE, et al. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 1999; 25:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/41\">",
"      Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008; 15:3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/42\">",
"      Brady MS, Brown K, Patel A, et al. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006; 13:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/43\">",
"      Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008; 15:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/44\">",
"      Kroon HM, Lin DY, Kam PC, Thompson JF. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Ann Surg 2009; 249:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/45\">",
"      Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer 2009; 115:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/46\">",
"      Kroon HM, Moncrieff M, Kam PC, Thompson JF. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol 2009; 16:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/47\">",
"      Kroon HM, Lin DY, Kam PC, Thompson JF. Major amputation for irresectable extremity melanoma after failure of isolated limb infusion. Ann Surg Oncol 2009; 16:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/48\">",
"      Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009; 208:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/49\">",
"      Calvo DB 3rd, Patt YZ, Wallace S, et al. Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy. Cancer 1980; 45:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/50\">",
"      Calabro A, Singletary SE, Carrasco CH, Legha SS. Intraarterial infusion chemotherapy in regionally advanced malignant melanoma. J Surg Oncol 1990; 43:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/51\">",
"      Eton O, East M, Legha SS, et al. Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases. Melanoma Res 1999; 9:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/52\">",
"      Roberts MS, Wu ZY, Siebert GA, et al. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 2001; 11:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/53\">",
"      Lindn&eacute;r P, Thompson JF, De Wilt JH, et al. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 2004; 30:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/54\">",
"      Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 2011; 213:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/55\">",
"      Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/56\">",
"      Klaase JM, Kroon BB, van Geel AN, et al. Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs? Melanoma Res 1994; 4 Suppl 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/57\">",
"      Brobeil A, Berman C, Cruse CW, et al. Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. Ann Surg Oncol 1998; 5:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/58\">",
"      Li&eacute;nard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/59\">",
"      Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/60\">",
"      Fraker, DL, Alexander, HR, Bartlett, DL, Rosenberg, SA. A prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF), and interferon -- an initial report (abstract). Proc Society of Surgical Oncology 1996; 49:6a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/61\">",
"      Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/62\">",
"      Kroon HM, Lin DY, Kam PC, Thompson JF. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann Surg Oncol 2009; 16:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/63\">",
"      Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004; 139:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/64\">",
"      Bartlett DL, Ma G, Alexander HR, et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997; 80:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/65\">",
"      Gr&uuml;nhagen DJ, van Etten B, Brunstein F, et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 2005; 12:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/66\">",
"      Hafstr&ouml;m L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991; 9:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27081/abstract/67\">",
"      Ghussen F, Kr&uuml;ger I, Groth W, St&uuml;tzer H. The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 1988; 61:654.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7608 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27081=[""].join("\n");
var outline_f26_28_27081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Primary tumor stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nodal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anatomic site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Influence of node dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Positive resection margins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - SLN biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Isolated limb perfusion or infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Perfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Perfusion versus infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1579472546\">",
"      Unresectable in transit metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1579472656\">",
"      Resected in transit recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1579472671\">",
"      High-risk primary melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intralesional therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adjuvant systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7608\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7608|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/9/17558\" title=\"figure 1\">",
"      Isolated limb infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7608|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/42/8869\" title=\"picture 1\">",
"      Melanoma in transit met",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7608|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 1A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 1B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34007?source=related_link\">",
"      Cutaneous melanoma: Management of local recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=related_link\">",
"      Cytotoxic chemotherapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=related_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15450?source=related_link\">",
"      Imaging studies in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=related_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=related_link\">",
"      Role of radiation therapy in the management of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=related_link\">",
"      Staging work-up and surveillance after treatment of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_28_27082="Pulmonary complications of sickle cell disease";
var content_f26_28_27082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary complications of sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27082/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27082/contributors\">",
"     Samuel I Hammerman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27082/contributors\">",
"     Harrison W Farber, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27082/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/28/27082/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27082/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/28/27082/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/28/27082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sickle cell disease (SCD) encompasses a group of hemoglobinopathies characterized by a single amino acid substitution in the beta globin chain. Hemoglobin S results from the substitution of a valine for glutamic acid as the sixth amino acid of the beta globin chain. The resulting hemoglobin tetramer",
"    <span class=\"nowrap\">",
"     (alpha2/betaS2)",
"    </span>",
"    is poorly soluble when deoxygenated. This deoxygenated hemoglobin polymerizes into sheets of elongated rope-like fibers, causing a marked decrease in red cell deformability and distortion of the cell into the classic crescent or sickle shape (",
"    <a class=\"graphic graphic_picture graphicRef64449 \" href=\"UTD.htm?1/42/1703\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequently occurring form of SCD is sickle cell anemia (HbSS), followed by HbSC disease and sickle hemoglobin-beta thalassemia. In the United States, 6 to 10 percent of African-American newborns have sickle cell trait [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/1\">",
"     1",
"    </a>",
"    ]. Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of HbSS. Vasoocclusion results in recurrent painful episodes (previously called sickle cell crisis) and a variety of serious organ system complications that can lead to life-long disabilities and premature death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The polymerization of deoxyhemoglobin (Hb)S the primary pathophysiologic event responsible for vaso-occlusive complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/2\">",
"     2",
"    </a>",
"    ]. However, polymerization alone does not account for the pathophysiology of SCD. Subsequent changes in red cell membrane structure and function, disordered cell volume control, and increased adherence to vascular endothelium also play an important role [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=see_link\">",
"     \"Vasoocclusion in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute and chronic pulmonary complications occur frequently in patients with SCD, and represent the most common cause of death from SCD in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. Although the pathogenesis of chronic pulmonary disease in SCD has not been clearly defined, recurrent microvascular obstruction resulting in the development of pulmonary hypertension, endothelial dysfunction, and parenchymal fibrosis is probably the primary mechanism (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Chronic disease'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues relating to the pulmonary manifestations of sickle cell disease will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. Other aspects of sickle cell disease are presented separately. A review of the acute chest syndrome in children and adolescents is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16810?source=see_link\">",
"     \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary acute pathologic processes that affect the lungs of patients with SCD include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Embolic phenomena due to bone marrow infarction and fat emboli",
"     </li>",
"     <li>",
"      Infarction caused by in-situ thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two other factors may contribute to acute pulmonary dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rib and sternal infarctions, which can lead to hypoventilation, have been demonstrated with bone scanning in patients with the acute chest syndrome (ACS, see below) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Splinting due to local pain results in atelectasis with hypoxemia, which promotes further intravascular sickling and the development of ACS.",
"     </li>",
"     <li>",
"      Pulmonary edema may develop secondary to excessive hydration, with possible contributions from concurrent blood transfusions or opiate use, both of which can increase pulmonary vascular permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"       \"Transfusion-related acute lung injury (TRALI)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Distinguishing among these disorders in the patient who presents with acute respiratory insufficiency is difficult, and several abnormalities may be present at the same time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute chest syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute chest syndrome (ACS) is the most common form of acute pulmonary disease in patients with SCD, occurring in almost one-half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/5,18\">",
"     5,18",
"    </a>",
"    ]. It is the most frequently reported cause of death in adults, is a risk factor for early mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/7-9,19\">",
"     7-9,19",
"    </a>",
"    ], and in two reports was the most common cause for admission of an adult or a child with SCD to an intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Reviews of the acute chest syndrome in children, adolescents, and adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16810?source=see_link\">",
"     \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9066?source=see_link\">",
"     \"Acute chest syndrome in adults with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A working definition of ACS is the presence of the following signs and symptoms in a patient with sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/13,22,23\">",
"     13,22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of a new pulmonary infiltrate, not due to atelectasis, involving at least one complete lung segment",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Temperature &gt;38.5&ordm;C",
"     </li>",
"     <li>",
"      Tachypnea, wheezing, or cough",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise etiology of ACS is unclear. Cigarette smoking and exposure to environmental tobacco smoke are possible risk factors for ACS, and may be one of the few potentially modifiable risk factors for this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of different possible causes of ACS was best studied in a 30-center cooperative study that included 671 episodes of ACS in 538 patients with sickle cell disease, most of whom were children or adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/22\">",
"     22",
"    </a>",
"    ]. The following distribution was noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unknown cause &mdash; 46 percent overall and 30 percent in patients with complete data",
"     </li>",
"     <li>",
"      Pulmonary infarction &mdash; 16 percent",
"     </li>",
"     <li>",
"      Fat embolism, with or without infection &mdash; 9 percent",
"     </li>",
"     <li>",
"      Chlamydophila (formerly Chlamydia) pneumoniae infection &mdash; 7 percent",
"     </li>",
"     <li>",
"      Mycoplasma pneumoniae infection &mdash; 7 percent",
"     </li>",
"     <li>",
"      Viral infection &mdash; 6 percent (eg, respiratory syncytial virus, parvovirus, rhinovirus)",
"     </li>",
"     <li>",
"      Mixed infections &mdash; 4 percent",
"     </li>",
"     <li>",
"      Other pathogens &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most infections are related to community-acquired pneumonia, while infarction generally results from in-situ thrombosis due to intravascular sickling and occlusion in the microvasculature, rather than macrovascular obstruction caused by embolization of venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/19,26-28\">",
"     19,26-28",
"    </a>",
"    ]. The hypoxia-induced adhesion of sickle erythrocytes to the pulmonary endothelium appears to be mediated by multiple factors, including endothelial cell VCAM-1 (vascular cell adhesion molecule-1), endothelin-1, cell-free hemoglobin, and nitric oxide metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/4,5,29,30\">",
"     4,5,29,30",
"    </a>",
"    ]. In addition, increased levels of F2 isoprostanes, which are markers of free radical catalyzed lipid peroxidation, have been noted in ACS, suggesting that increased oxidative stress may have a pathogenetic role [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary fat embolism (PFE) also appears to play a significant role in the development of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/22\">",
"     22",
"    </a>",
"    ]. Bronchoalveolar lavage fluid findings of greater than 5 percent lipid laden macrophages (results consistent with the diagnosis of fat embolism) have been found in 50 to 60 percent of children and adults with ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Patients with PFE are more likely to complain of bone pain and may develop neurologic symptoms, a finding not seen in ACS without PFE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Fat and bone marrow embolism'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ACS initially present with fever, chest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extremity pain, dyspnea, and nonproductive cough [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/34\">",
"     34",
"    </a>",
"    ]. Examination of the chest may reveal local tenderness over the ribs or sternum; findings of pulmonary consolidation may also be noted. Common laboratory findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Leukocytosis",
"     </li>",
"     <li>",
"      Thrombocytopenia or thrombocytosis",
"     </li>",
"     <li>",
"      Falling hemoglobin concentration",
"     </li>",
"     <li>",
"      Elevations in lactate dehydrogenase and bilirubin levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the chest radiograph may be normal in one-third of cases on admission, most patients will develop lower lobe infiltrates (which are bilateral in one-third). Pleural effusions are present in 25 to 35 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/35\">",
"     35",
"    </a>",
"    ]. Worsening infiltrates and hypoxemia are a harbinger of the development of acute respiratory failure and possibly multisystem organ failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In one series, bacteremia was present in 3.5 percent of patients with ACS, particularly infants (14 percent versus 1.8 percent in those over 10 years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 30-center cooperative study, which included 671 episodes of ACS in 538 patients with sickle cell disease, the following symptoms were present at the time of diagnosis of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever &mdash; 80 percent",
"     </li>",
"     <li>",
"      Cough &mdash; 62 percent",
"     </li>",
"     <li>",
"      Tachypnea &mdash; 45 percent",
"     </li>",
"     <li>",
"      Chest pain &mdash; 44 percent",
"     </li>",
"     <li>",
"      Shortness of breath &mdash; 41 percent",
"     </li>",
"     <li>",
"      Arm and leg pain &mdash; 37 percent",
"     </li>",
"     <li>",
"      Abdominal pain &mdash; 35 percent",
"     </li>",
"     <li>",
"      Rib or sternal pain &mdash; 21 percent",
"     </li>",
"     <li>",
"      Wheezing &mdash; 13 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;No current laboratory or radiographic finding permits the differentiation of ACS from other acute pulmonary manifestations of SCD, including pneumonia and infarction. The finding of positive blood cultures associated with a pulmonary infiltrate should be treated as infectious pneumonia until proven otherwise. The diagnostic evaluation of possible community-acquired pneumonia is similar in patients with or without SCD, and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cytologic samples obtained via bronchoalveolar lavage or sputum induction may reveal alveolar macrophages containing fat droplets following pulmonary fat embolism, but the diagnostic and prognostic value of this finding in patients with ACS has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differentiation of pulmonary infarction due to thromboembolic phenomena from ACS remains problematic. Difficulties establishing the diagnosis of pulmonary infarction can be attributed to the lack of evidence for deep venous thrombosis in the majority of patients, abnormal ventilation-perfusion scans in patients with SCD at baseline, and uncertainty about whether contrast studies can be performed safely in these patients given the possible association with further sickling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute treatment of ACS is primarily supportive and is based upon the potential etiologic factors described above [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/22,41\">",
"     22,41",
"    </a>",
"    ]. Although microbiologic data are infrequently diagnostic, antibiotic regimens that include coverage for community acquired and atypical organisms should be employed, such as a second-generation cephalosporin with or without a macrolide. In addition, use of supplemental oxygen to maintain a PaO2 of 70 to 100 mmHg is critical in preventing further intravascular sickling. Opioid analgesics should be used judiciously to avoid potential respiratory depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asthma and atopy are common in patients with SCD, and bronchoprovocation studies suggest that up to two-thirds of patients with SCD have increased airway reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In a mouse model, animals with SCD and experimentally-induced asthma were more susceptible to pulmonary inflammation and death than control mice, suggesting that asthma contributes significantly to morbidity and mortality in SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although no randomized trials have been performed, one large study noted clinical improvement in 20 percent of patients with ACS who were treated with inhaled bronchodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/22,46\">",
"     22,46",
"    </a>",
"    ]. We recommend inhaled beta agonist therapy in patients with evidence of wheezing, severe respiratory compromise, clinical or radiographic evidence of hyperinflation, or a prior history of asthma or obstructive airway disease. Bronchospasm should also be considered during mechanical ventilation in patients with respiratory failure; these patients should also be treated with bronchodilators. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Volume depletion contributes to sickling phenomena. As a result, hydration has been a standard therapy in the treatment of both vasoocclusive crisis and ACS. However, some evidence suggests that vigorous hydration in combination with opioid analgesics can lead to pulmonary edema. As a result, frequent clinical evaluation of these patients is required, and the maintenance of a euvolemic state is the treatment goal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unless thromboembolic phenomena are documented, empiric anticoagulant therapy is NOT recommended because of the potential risk of intracranial and renal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link\">",
"     \"Renal manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Incentive spirometry (used for the prevention of atelectasis after rib or sternal infarction) appears to be effective in the prevention of pulmonary complications (atelectasis and infiltrates) associated with ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormal nitric oxide metabolism has been implicated as a contributing factor in patients with ACS, and inhaled nitric oxide (NO) is under investigation as a potential therapy in this situation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/19,28,29\">",
"     19,28,29",
"    </a>",
"    ]. Inhaled NO may act in part by reducing the adhesion of sickle erythrocytes to the pulmonary endothelium, an effect that may be mediated by downregulation of VCAM-1 expression in pulmonary endothelial cells exposed to hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/27-29,48\">",
"     27-29,48",
"    </a>",
"    ]. In anecdotal reports, inhaled NO has been effective in patients with severe ACS and larger trials are ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Although inhaled NO has been approved by the Food and Drug Administration for the treatment of neonatal pulmonary hypertension, it is premature to use this agent in patients with ACS, except in the setting of clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/28,51\">",
"     28,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple transfusion of leukocyte-depleted red cells that are negative for sickle cells and matched with respect to C, E, and Kell antigens has been shown to improve oxygenation and decrease the incidence of new red cell antibody formation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, simple red cell transfusion may excessively increase the patient's hematocrit and blood viscosity and further exacerbate the vasoocclusive event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=see_link&amp;anchor=H9#H9\">",
"     \"Vasoocclusion in sickle cell disease\", section on 'Blood viscosity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exchange transfusion has been recommended in the setting of progressive infiltrates and hypoxemia refractory to conventional therapy. Reduction of the HbS level to &lt;30 percent, along with a hematocrit of approximately 30 percent, can lead to marked improvement in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, there are no randomized studies comparing exchange to simple transfusion. The few available retrospective studies have indicated no difference in outcome between these two approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/22,54,55\">",
"     22,54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Preventing recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic therapy is largely aimed at preventing recurrent episodes in patients with a history of ACS. Recurrent vascular and parenchymal insults constitute the greatest risk factor for the development of sickle cell chronic lung disease (SCCLD) (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Chronic disease'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Penicillin prophylaxis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"     penicillin V potassium",
"    </a>",
"    125 mg twice daily) is recommended in children aged four months to at least three years. In addition, polyvalent pneumococcal vaccine should be given on a routine basis in both children and adults.",
"   </p>",
"   <p>",
"    The use of chronic transfusions decreases the frequency of ACS episodes but may lead to iron overload or transfusion-acquired infection. Such therapy, therefore, can only be recommended on an individual basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the management of sickle cell disease\", section on 'Transfusion therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    has been shown to decrease painful crises and episodes of ACS by 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/56\">",
"     56",
"    </a>",
"    ]. Although its clinical efficacy has been documented, current widespread use is hampered by difficulties with compliance, the need for frequent evaluation of peripheral blood counts, and uncertainty about long-term safety. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clinical outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 30-center cooperative study, which included 671 episodes of ACS in 538 patients with sickle cell disease, the following outcomes were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mean length of hospitalization was 10.5 days; patients who were &ge;20 years of age had a more severe course than those &le;20 years of age.",
"     </li>",
"     <li>",
"      Thirteen percent of patients required mechanical ventilation; 81 percent recovered.",
"     </li>",
"     <li>",
"      Neurologic events occurred in 11 percent, among whom 46 percent had respiratory failure.",
"     </li>",
"     <li>",
"      One-fifth of the patients treated with bronchodilators had clinical improvement.",
"     </li>",
"     <li>",
"      Three percent of patients died. The most common causes of death were pulmonary emboli and infectious bronchopneumonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one report, all five children with acute chest syndrome requiring endotracheal intubation and ventilatory support developed neurologic complications, including seizures, silent cerebral infarcts, cerebral hemorrhage, and reversible posterior leukoencephalopathy syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SCD are predisposed to develop pneumonia due to impaired host defenses, including loss of antibody protection (in the setting of auto-splenectomy), altered phagocytic function, and defective opsonization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Although most acute pulmonary infections were once thought to be due to pneumococcus, subsequent studies (particularly those in adults) have revealed an increasing frequency of infection with Haemophilus influenzae [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Mycoplasma pneumoniae and C. pneumoniae, which are common causes of community-acquired pneumonia, have been associated with both pneumonia and the subsequent development of acute chest syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/22,35,64-67\">",
"     22,35,64-67",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Acute chest syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Differentiation of isolated infectious pneumonia from acute chest syndrome (ACS) may be difficult, since cultures of blood and sputum are often nondiagnostic. Pneumonia is considered more likely in children (younger than five years of age), and in patients with upper lobe infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fat and bone marrow embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow infarction resulting from microvascular occlusion is the probable pathogenic mechanism common to the initiation of both fat and bone marrow embolism in patients with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. Patients with SCD and pulmonary fat embolism (PFE) frequently have mental status changes, thrombocytopenia, falling hematocrit, and severe hypoxemia, a clinical presentation similar to that in patients in whom PFE develops following the fracture of long bones [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=see_link\">",
"     \"Fat embolism syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although no current test is available for the definitive diagnosis of PFE, bronchoalveolar lavage (BAL) may have some utility [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. One report, for example, evaluated 27 patients with SCD and ACS; 12 were diagnosed with PFE by assessing the fat content in pulmonary macrophages obtained from bronchoalveolar lavage (BAL) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/32\">",
"     32",
"    </a>",
"    ]. The patients diagnosed with PFE had a higher incidence of chest pain and neurologic symptoms, and lower hemoglobin and platelet levels than those without a BAL diagnosis of PFE, all trends suggestive of the clinical diagnosis of fat embolism. However, the diagnostic and prognostic utility of bronchoscopy in PFE has not been universal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/73\">",
"     73",
"    </a>",
"    ], and therefore BAL remains a research tool at present.",
"   </p>",
"   <p>",
"    Treatment options in selected patients with clinical and laboratory findings consistent with PFE may include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exchange transfusion",
"     </li>",
"     <li>",
"      Plasma infusions",
"     </li>",
"     <li>",
"      Glucocorticoids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of glucocorticoids in this setting, however, requires further study, as benefit has been most definitively demonstrated when glucocorticoids are administered prophylactically, rather than after the development of the clinical syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/74-77\">",
"     74-77",
"    </a>",
"    ]. Our management of severe PFE has generally involved use of exchange transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy data of the lungs of patients with SCD reveal fibrin thromboembolism in larger arteries with or without infarction, and extensive thrombosis in smaller arteries (in-situ thrombosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/26,69,72\">",
"     26,69,72",
"    </a>",
"    ]. The frequency of large vessel fibrin thromboembolism in patients with SCD is not increased from that found in an equivalent age, sex, and race matched population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/69\">",
"     69",
"    </a>",
"    ]. As a result, pulmonary infarction in patients with SCD is assumed to be due to microvascular occlusion and subsequent in-situ thrombosis. Patients with HbSC have an increased incidence of thrombosis compared with those with HbSS, secondary to an elevation in blood viscosity and hematocrit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of potential venous thromboembolic disease in patients with SCD is performed similarly to that in a patient without sickle disease. However, caution in the interpretation of ventilation- perfusion scans is advisable due to baseline abnormalities in SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of hypertonic contrast agents during pulmonary angiography has been associated with the precipitation of intravascular sickling. The use of newer contrast media, however, may possibly be safer in these patients and is our preference. Furthermore, anticoagulation should only be used once venous thromboembolism has been documented because of the increased risk of intracranial or renal bleeding in patients with HbSS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CHRONIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmortem studies of patients with SCD often show evidence of pulmonary vascular bed obliteration, smooth muscle hypertrophy, and parenchymal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/10,26,69,72\">",
"     10,26,69,72",
"    </a>",
"    ]. Sickle cell chronic lung disease (SCCLD) is characterized clinically by the development of pulmonary hypertension and cor pulmonale in association with restrictive lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/11,79-81\">",
"     11,79-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sickle cell chronic lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCCLD may begin to develop as early as the second decade of life. Pulmonary dysfunction rapidly progresses, with death occurring within seven years of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/11\">",
"     11",
"    </a>",
"    ]. Significant risk factors for SCCLD include recurrent episodes of ACS, painful crises, and aseptic bone necrosis.",
"   </p>",
"   <p>",
"    Patients characteristically progress through four clinical stages based upon physiologic and radiographic data and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1 - recurrent chest pain and cough, mild reductions in forced vital capacity (FVC) and total lung capacity (TLC), normal oxygen saturation, and near normal chest radiographs with slightly increased interstitial markings.",
"     </li>",
"     <li>",
"      Stage 2 - greater pain than stage 1, moderate reductions in FVC and TLC, normal oxygen saturation, and diffuse interstitial fibrosis (all lobes on chest radiograph).",
"     </li>",
"     <li>",
"      Stage 3 - severe, crushing chest pain, hypoxemia during stable periods (PO2 approximately 70 mmHg), severe reductions in FVC and TLC, and pulmonary fibrosis on chest imaging.",
"     </li>",
"     <li>",
"      Stage 4 - prolonged chest pain, fixed dyspnea, hypoxemia at rest, severe pulmonary fibrosis on chest radiograph, and elevated pulmonary artery pressure at rest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Obstructive sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper airway obstruction during sleep due to adenoid and tonsillar enlargement has been found in up to one-third of children with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. Episodic hypoxemia can occur, with marked improvement following adenotonsillectomy. Despite this observation, there are no current recommendations regarding screening studies for sleep apnea in SCD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Alterations in baseline pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different parameters of pulmonary function are altered in patients with sickle cell lung disease. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total lung capacity and vital capacity may be reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/85,86\">",
"       85,86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Arterial oxygen saturation (SaO2) is reduced, with steady-state baseline values below 96 percent in an appreciable percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H36#H36\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Oxygen saturation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Even when corrected for anemia, the diffusing capacity for carbon monoxide (DLCO) is abnormally low, particularly in patients with a history of the acute chest syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/85,86\">",
"       85,86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The alveolar-arterial difference is widened both at rest and with exercise, which most likely results from ventilation and perfusion abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mild to moderate airflow obstruction may be present, particularly among patients with recurrent episodes of acute chest syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a cross-sectional evaluation from the Cooperative Study of Sickle Cell Disease, pulmonary function was assessed in 310 adult African-American subjects homozygous for Hb S disease. The following patterns were found [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Restrictive pattern &mdash; 74 percent",
"     </li>",
"     <li>",
"      Isolated low DLCO &mdash; 13 percent",
"     </li>",
"     <li>",
"      Normal pattern &mdash; 10 percent",
"     </li>",
"     <li>",
"      Mixed",
"      <span class=\"nowrap\">",
"       obstructive/restrictive",
"      </span>",
"      pattern &mdash; 2 percent",
"     </li>",
"     <li>",
"      Obstructive pattern &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patterns were not significantly different between subjects with or without a prior history of acute chest syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PULMONARY HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension is a frequent chronic and severe complication of SCD. In this section, its prevalence, prognosis, pathogenesis, screening, and treatment are discussed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies have estimated that the prevalence of pulmonary hypertension in patients with SCD is 20 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/10,80,88-91\">",
"     10,80,88-91",
"    </a>",
"    ]. Evidence for this complication has been found in children with SCD as young as three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These findings were supported by a prospective observational study of 195 adults with SCD, which detected pulmonary hypertension in 32 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/93\">",
"       93",
"      </a>",
"      ]. Hemolysis, chronic anemia, and the need for frequent transfusions were predictors of pulmonary hypertension in this study.",
"     </li>",
"     <li>",
"      A similar prospective study found evidence for pulmonary hypertension (ie, an elevated tricuspid regurgitant jet velocity (TRV) &gt;2.5",
"      <span class=\"nowrap\">",
"       m/second",
"      </span>",
"      on cardiac echocardiography) in 30 percent of 62 children &gt;6 years of age with homozygous SS disease or Sbeta(0) thalassemia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/94\">",
"       94",
"      </a>",
"      ]. Risk factors for pulmonary hypertension, which was seen only in the children with homozygous SS disease, included increased reticulocyte count, low oxygen saturation, and high platelet count.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies have looked at pulmonary hypertension collectively and have not tried to determine the prevalence of the different types of pulmonary hypertension. Thus, it is unknown whether patients who have SCD plus pulmonary hypertension have intrinsic pulmonary vascular disease (ie, group 1 pulmonary arterial hypertension), pulmonary hypertension due to left heart disease (eg, group 2 pulmonary hypertension), or an alternative type of pulmonary hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The studies described above used echocardiographic criteria as a screening tool to identify pulmonary hypertension. However, echocardiography is no longer considered sufficient to confirm pulmonary hypertension. Right heart catheterization is now required, although the effect of the diagnostic modality on prevalence estimates is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link&amp;anchor=H17914506#H17914506\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Diagnostic criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Right heart catheterization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 398 outpatients with sickle cell disease (mean age 34 years), the prevalence of a tricuspid regurgitant jet velocity of at least 2.5",
"      <span class=\"nowrap\">",
"       m/second",
"      </span>",
"      on echocardiography was 27 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/95\">",
"       95",
"      </a>",
"      ]. In contrast, the prevalence of pulmonary hypertension as confirmed by right heart catheterization (ie, mean pulmonary artery pressure of at least 25 mm Hg) was only 6 percent, resulting in a positive predictive value of echocardiography of only 25 percent. Among the 24 patients with confirmed pulmonary hypertension, the pulmonary-capillary wedge pressure was 15 mm Hg or less (indicating precapillary pulmonary hypertension) in 11 patients.",
"     </li>",
"     <li>",
"      In a second study of 531 adults with sickle cell disease who were screened by echocardiography, 84 (15.8 percent) underwent right heart catheterization. A total of 55 patients were found to have pulmonary hypertension by right heart catheterization, for an estimated prevalence of 10 to 11 percent. However, not all subjects with indications for right heart catheterization underwent this procedure, leaving the 10 to 11 percent magnitude of pulmonary hypertension found in this study in question [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent vascular and parenchymal insults constitute the greatest risk factor for the development of sickle cell chronic lung disease (SCCLD). Pulmonary hypertension is accentuated by, and is significantly correlated with, vasoocclusive events, exercise, and red cell hemolysis resulting in increased plasma levels of cell-free hemoglobin, which rapidly depletes the potent pulmonary vasodilator nitric oxide (NO) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/13,93,97-100\">",
"     13,93,97-100",
"    </a>",
"    ], although there is continuing disagreement on the validity of the evidence in favor of the latter point [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This effect appears to be compounded by a number of other factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated plasma levels of arginase, also released from red cells, limiting bioavailability of L-arginine, the substrate for NO synthesis (",
"      <a class=\"graphic graphic_figure graphicRef79786 \" href=\"UTD.htm?27/52/28494\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/100,104-106\">",
"       100,104-106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor that may also be an independent risk factor for endothelial dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/107\">",
"       107",
"      </a>",
"      ]. In a study of 177 patients with sickle cell disease and 29 controls, ADMA levels correlated with markers of hemolysis, low oxygen saturation, pulmonary hypertension, and early death. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H1269197#H1269197\">",
"       \"Overview of the possible risk factors for cardiovascular disease\", section on 'Asymmetrical dimethylarginine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these effects on endothelial regulation, increased levels of cell-free hemoglobin may also contribute to vascular smooth muscle dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/108\">",
"     108",
"    </a>",
"    ]. These mechanisms may also lead to pulmonary hypertension and other vascular complications in patients with thalassemia or other hematologic disorders associated with high rates of hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=see_link&amp;anchor=H3#H3\">",
"     \"Inhaled nitric oxide in adults with pulmonary hypertension\", section on 'Physiology'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In one study, plasma arginase activity was significantly elevated in 228 patients with SCD as compared with 36 controls; the highest activity was seen in those with secondary pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/112\">",
"     112",
"    </a>",
"    ]. Lower bioavailability of arginine, as reflected by a low ratio of arginine to ornithine, was associated with markers of inflammation and soluble adhesion molecules, greater severity of pulmonary hypertension, and a significantly increased risk of mortality (RR 2.5, 95% CI 1.2-5.2).",
"   </p>",
"   <p>",
"    Another factor that could limit NO bioavailability and contribute to pulmonary hypertension is the oxidant status of SCD patients and the effect of redox state on NO bioavailability. The predominant activity of NO as a vasodilator and an inhibitor of platelet aggregation occurs when it reacts with thiols, primarily on albumin, to form R-nitrosothiols (RSNO) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/113\">",
"     113",
"    </a>",
"    ]. However, NO reacts with several other compounds to create reactive species, including oxygen (O2, resulting in formation of nitrogen dioxide [NO2]),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    (H2O2, resulting in formation of NO2 and nitrate [NO3]), and superoxide (O2-, resulting in formation of the powerful oxidant peroxynitrite [ONOO-]).",
"   </p>",
"   <p>",
"    Several abnormalities in the redox state have been noted in SCD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study demonstrated decreases in the anti-oxidants glutathione reductase and thiols as well as the formation of ONOO- in cultured endothelial cells exposed to plasma from patients with acute chest syndrome (ACS) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/114\">",
"       114",
"      </a>",
"      ]. These findings suggest a preferential shunting of NO towards its oxidative metabolites.",
"     </li>",
"     <li>",
"      Another report observed increased ONOO- formation in both transgenic sickle cell mice and autopsy specimens of SCD patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased levels and activity of catalase and superoxide dismutase (SOD) have been observed in sickle RBC suggesting increased availability of H2O2 and O2-, both of which could react with NO to form toxic metabolites [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/116,117\">",
"       116,117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an additional study, levels of red cell glutathione and its precursor glutamine were significantly lower in patients with SCD than in healthy volunteers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/118\">",
"       118",
"      </a>",
"      ]. The ratio of glutamine to glutamate correlated inversely with tricuspid regurgitant jet velocity (TRV), plasma arginase concentration, and plasma free hemoglobin level, linking red cell glutamine depletion to dysregulation of the arginine-NO pathway, increased oxidative stress, and increased hemolysis.",
"     </li>",
"     <li>",
"      Using serum levels of F2 isoprostanes as a reflection of redox state, one report noted a ninefold increase in their level during ACS, and a sixfold increase compared with SCD patients at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/31,119\">",
"       31,119",
"      </a>",
"      ]. The high degree of variability in isoprostane levels, both at baseline and during crisis in these patients, suggests inherent differences in the susceptibility of SCD patients to oxidative stress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic variability which might contribute to the development of pulmonary hypertension in patients with SCD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical variability in sickle cell anemia\", section on 'Pulmonary hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of pulmonary hypertension requires right heart catheterization. However, noninvasive measures that may help identify patients whose SCD is complicated by pulmonary hypertension include plasma levels of brain natriuretic peptide (BNP) and a six-minute walk test (6MWT) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/95,97,120,121\">",
"     95,97,120,121",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Multicenter Study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       Hydroxyurea",
"      </a>",
"      in Sickle Cell Anemia (MSH study) found that BNP &gt;160",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      had a sensitivity, specificity, and positive predictive value of 57, 91, and 78 percent, respectively, in detecting pulmonary hypertension, as defined by echocardiographic criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/97\">",
"       97",
"      </a>",
"      ]. BNP levels correlated directly with mortality (RR 2.87, 95% CI 1.2-6.6) and indirectly with hemoglobin levels. However, BNP levels did not correlate with rates of painful episodes, acute chest syndrome, or the use of hydroxyurea.",
"     </li>",
"     <li>",
"      In a controlled observational study, a 6MWT was performed in 17 patients with SCD alone and 26 patients with SCD plus pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/120\">",
"       120",
"      </a>",
"      ]. Patients with SCD plus pulmonary hypertension walked a shorter distance during the 6MWT (320 versus 435 meters). The 6MWT distance inversely correlated with the mPAP as measured by right heart catheterization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While an elevated BNP or a decreased 6MWT distance provides additional evidence that pulmonary hypertension may exist, neither measure should be considered diagnostic of coexisting pulmonary hypertension. In both studies, significant overlap occurred between patients who have SCD alone and patients who have SCD plus pulmonary hypertension, indicating that BNP and the 6MWT distinguish the two groups poorly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the management of sickle cell disease-associated pulmonary hypertension are limited. The use of exchange transfusion supplemented with nocturnal or continuous oxygen as required has been suggested, although randomized trials of this and other approaches are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/122,123\">",
"     122,123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the poor survival of patients with pulmonary hypertension, trials of therapy with prostacyclin and other agents capable of reducing PA pressure (eg, endothelin receptor antagonists, inhibition of placenta growth factor signaling) appear warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/10,124-126\">",
"     10,124-126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Advanced therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13342776\">",
"    <span class=\"h4\">",
"     Sildenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is early information on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    or other selective phosphodiesterase inhibitors in the management of patients with pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. However, a randomized trial examining the safety and efficacy of sildenafil in patients with sickle cell anemia and pulmonary hypertension (walk test for Pulmonary Hypertension and Sickle Cell Disease with Sildenafil; walk-PHaSST) was stopped early because patients assigned to treatment with sildenafil were significantly more likely to have sickle cell pain crises resulting in hospitalization than those assigned to receive placebo (35 versus 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/129\">",
"     129",
"    </a>",
"    ]. In addition, there was no evidence of a beneficial treatment effect on 6-minute walk distance, tricuspid regurgitation velocity, or N-terminal pro-brain natriuretic peptide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13342783\">",
"    <span class=\"h4\">",
"     Arginine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early clinical experience with oral arginine supplementation suggests that this approach reduces pulmonary hypertension in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. In an uncontrolled, prospective single-center study, oral arginine supplementation (0.1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    PO three times per day for 5 days) resulted in a 15 percent decrease in mean pulmonary artery pressure as assessed by echocardiography (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Pulmonary hypertension'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods to reduce red cell hemolysis, such as the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (HU), are also likely to be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/91\">",
"     91",
"    </a>",
"    ]. As an example, 10 children with moderate or persistent elevation in pulmonary pressure (ie, elevated TRV on echocardiography) were offered treatment with HU, with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/132\">",
"     132",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TRV decreased, along with improvement in hemoglobin concentration and oxygen saturation and a significant reduction in mean right ventricular pressure in all five children who agreed to receive HU treatment.",
"     </li>",
"     <li>",
"      One of these five children stopped HU at 10 months; repeat echocardiography two months later showed an increase in TRV back towards high baseline levels.",
"     </li>",
"     <li>",
"      In the five children who either were noncompliant with HU or refused treatment, repeat echocardiograms showed persistent elevation of TRV on follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This was a small, uncontrolled study with very short follow-up. Its long-term clinical relevance is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival is decreased among both children and adults whose SCD is complicated by pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/81,93,96,133,134\">",
"     81,93,96,133,134",
"    </a>",
"    ]. In the prospective observational study described above, pulmonary hypertension was associated with an increased risk of death (RR 10.1, 95% CI 2.2-47) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/93\">",
"     93",
"    </a>",
"    ]. In another study, 34 patients with SCD underwent right heart catheterization for suspected pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/81\">",
"     81",
"    </a>",
"    ]. Pulmonary hypertension was confirmed in 20 patients (average mean pulmonary artery pressure [mPAP] 36 mm Hg) and excluded in 14 patients (average mPAP 18 mm Hg). Each 10 mmHg rise in the mPAP was associated with a 1.7-fold increase in mortality. The median survival was 26 months for patients with pulmonary hypertension, whereas 70 percent of patients without pulmonary hypertension were still alive at the end of the nearly 10-year study.",
"   </p>",
"   <p>",
"    In one study, subjects with hemoglobin SC disease or sickle-beta(+) thalassemia were significantly less likely than those with homozygous SS disease to develop pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/135\">",
"     135",
"    </a>",
"    ]. However, those subjects with SC disease who did develop pulmonary hypertension remained at a significant risk for death during 49 months of follow-up (hazard ratio 8.2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SICKLE CELL TRAIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although organ dysfunction is rare in patients with sickle cell trait, pulmonary infarction, acute chest syndrome, and sudden death during intense military training have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/136-138\">",
"     136-138",
"    </a>",
"    ]. However, minimal difference in exercise tolerance and pulmonary function either at sea level or at altitude has been observed between patients with sickle cell trait and matched normals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/28/27082/abstract/139-145\">",
"     139-145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since sickle cell trait individuals have an increased prevalence of isosthenuria with age, dehydration may be a risk factor in sudden death among sickle cell trait individuals with limited fluid replacement. It is therefore indicated that all sickle cell trait individuals, as well as other athletes, follow aggressive hydration and conditioning precautions during exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=see_link&amp;anchor=H14#H14\">",
"     \"Sickle cell trait\", section on 'Risk for sudden death and athletic participation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18977349\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute and chronic pulmonary complications secondary to recurrent microvascular obstruction represent the most common causes of death from sickle cell disease (SCD) in adulthood.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acute",
"      </strong>",
"      &mdash; Acute pulmonary complications of SCD include infection (pneumonia), embolic phenomena due to bone marrow infarction and fat emboli, infarction caused by in-situ thrombosis, acute chest syndrome, and venous thromboembolism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The acute chest syndrome is one of the most feared acute complications of SCD. Diagnosis and management of this complication are discussed in depth separately. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute chest syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16810?source=see_link\">",
"       \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9066?source=see_link\">",
"       \"Acute chest syndrome in adults with sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chronic",
"      </strong>",
"      &mdash; Long-term pulmonary complications of SCD include chronic lung disease, obstructive sleep apnea, non-specific alterations in pulmonary function, and pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Chronic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pulmonary hypertension is the most severe of the chronic pulmonary complications of SCD, resulting in decreased survival among both children and adults with this complication. Options for the management of this complication are limited. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Pulmonary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lung disease in sickle cell trait",
"      </strong>",
"      &mdash; Lung dysfunction is rare in patients with sickle cell trait, although pulmonary infarction, acute chest syndrome, and sudden death during intense military training and other forms of intense exertion have been reported. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Sickle cell trait'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=see_link&amp;anchor=H9#H9\">",
"       \"Sickle cell trait\", section on 'Complications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/1\">",
"      Castro O, Rana SR, Bang KM, Scott RB. Age and prevalence of sickle-cell trait in a large ambulatory population. Genet Epidemiol 1987; 4:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/2\">",
"      Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/3\">",
"      Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/4\">",
"      Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol 2004; 76:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/5\">",
"      Minter KR, Gladwin MT. Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research. Am J Respir Crit Care Med 2001; 164:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/6\">",
"      Siddiqui AK, Ahmed S. Pulmonary manifestations of sickle cell disease. Postgrad Med J 2003; 79:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/7\">",
"      Gray A, Anionwu EN, Davies SC, Brozovic M. Patterns of mortality in sickle cell disease in the United Kingdom. J Clin Pathol 1991; 44:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/8\">",
"      Thomas AN, Pattison C, Serjeant GR. Causes of death in sickle-cell disease in Jamaica. Br Med J (Clin Res Ed) 1982; 285:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/9\">",
"      Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/10\">",
"      Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol 2005; 129:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/11\">",
"      Powars D, Weidman JA, Odom-Maryon T, et al. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988; 67:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/12\">",
"      Vij R, Machado RF. Pulmonary complications of hemoglobinopathies. Chest 2010; 138:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/13\">",
"      Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/14\">",
"      Rucknagel DL. The role of rib infarcts in the acute chest syndrome of sickle cell diseases. Pediatr Pathol Mol Med 2001; 20:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/15\">",
"      Gelfand MJ, Daya SA, Rucknagel DL, et al. Simultaneous occurrence of rib infarction and pulmonary infiltrates in sickle cell disease patients with acute chest syndrome. J Nucl Med 1993; 34:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/16\">",
"      Quinn CT, Buchanan GR. The acute chest syndrome of sickle cell disease. J Pediatr 1999; 135:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/17\">",
"      Haynes J Jr, Allison RC. Pulmonary edema. Complication in the management of sickle cell pain crisis. Am J Med 1986; 80:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/18\">",
"      Johnson CS, Verdegem TD. Pulmonary complications of sickle cell disease. Semin Respir Med 1988; 9:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/19\">",
"      Gladwin MT, Schechter AN, Shelhamer JH, Ognibene FP. The acute chest syndrome in sickle cell disease. Possible role of nitric oxide in its pathophysiology and treatment. Am J Respir Crit Care Med 1999; 159:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/20\">",
"      Gardner K, Bell C, Bartram JL, et al. Outcome of adults with sickle cell disease admitted to critical care - experience of a single institution in the UK. Br J Haematol 2010; 150:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/21\">",
"      Bartram JL, Thein SL, Gardner K, et al. Outcome of children with sickle cell disease admitted to intensive care - a single institution experience. Br J Haematol 2010; 150:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/22\">",
"      Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/23\">",
"      Platt OS. The acute chest syndrome of sickle cell disease. N Engl J Med 2000; 342:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/24\">",
"      Young RC Jr, Rachal RE, Hackney RL Jr, et al. Smoking is a factor in causing acute chest syndrome in sickle cell anemia. J Natl Med Assoc 1992; 84:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/25\">",
"      Cohen RT, DeBaun MR, Blinder MA, et al. Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease. Blood 2010; 115:3852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/26\">",
"      Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 2002; 33:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/27\">",
"      Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 1999; 94:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/28\">",
"      Gladwin MT, Rodgers GP. Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. Lancet 2000; 355:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/29\">",
"      Pritchard KA Jr, Ou J, Ou Z, et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol 2004; 286:L705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/30\">",
"      Setty BN, Stuart MJ. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood 1996; 88:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/31\">",
"      Klings ES, Christman BW, McClung J, et al. Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. Am J Respir Crit Care Med 2001; 164:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/32\">",
"      Vichinsky E, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994; 83:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/33\">",
"      Godeau B, Schaeffer A, Bachir D, et al. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism. Am J Respir Crit Care Med 1996; 153:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/34\">",
"      Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997; 89:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/35\">",
"      Poncz M, Kane E, Gill FM. Acute chest syndrome in sickle cell disease: etiology and clinical correlates. J Pediatr 1985; 107:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/36\">",
"      Bone RC, Balk R, Slotman G, et al. Adult respiratory distress syndrome. Sequence and importance of development of multiple organ failure. The Prostaglandin E1 Study Group. Chest 1992; 101:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/37\">",
"      Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med 1994; 96:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/38\">",
"      Lechapt E, Habibi A, Bachir D, et al. Induced sputum versus bronchoalveolar lavage during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2003; 168:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/39\">",
"      Richards D, Nulsen FE. Angiographic media and the sickling phenomenon. Surg Forum 1971; 22:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/40\">",
"      Mekontso Dessap A, Deux JF, Abidi N, et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2011; 184:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/41\">",
"      Fawibe AE. Managing acute chest syndrome of sickle cell disease in an African setting. Trans R Soc Trop Med Hyg 2008; 102:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/42\">",
"      Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax 2005; 60:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/43\">",
"      Santoli F, Zerah F, Vasile N, et al. Pulmonary function in sickle cell disease with or without acute chest syndrome. Eur Respir J 1998; 12:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/44\">",
"      Leong MA, Dampier C, Varlotta L, Allen JL. Airway hyperreactivity in children with sickle cell disease. J Pediatr 1997; 131:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/45\">",
"      Nandedkar SD, Feroah TR, Hutchins W, et al. Histopathology of experimentally induced asthma in a murine model of sickle cell disease. Blood 2008; 112:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/46\">",
"      Knight-Madden JA, Hambleton IR. Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev 2003; :CD003733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/47\">",
"      Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995; 333:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/48\">",
"      Space SL, Lane PA, Pickett CK, Weil JV. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol 2000; 63:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/49\">",
"      Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology 1997; 87:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/50\">",
"      Sullivan KJ, Goodwin SR, Evangelist J, et al. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med 1999; 27:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/51\">",
"      Al Hajeri A, Serjeant GR, Fedorowicz Z. Inhaled nitric oxide for acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev 2008; :CD006957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/52\">",
"      Mallouh AA, Asha M. Beneficial effect of blood transfusion in children with sickle cell chest syndrome. Am J Dis Child 1988; 142:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/53\">",
"      Emre U, Miller ST, Gutierez M, et al. Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr 1995; 127:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/54\">",
"      Swerdlow PS. Red cell exchange in sickle cell disease. Hematology Am Soc Hematol Educ Program 2006; :48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/55\">",
"      Turner JM, Kaplan JB, Cohen HW, Billett HH. Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults. Transfusion 2009; 49:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/56\">",
"      Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/57\">",
"      Henderson JN, Noetzel MJ, McKinstry RC, et al. Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle cell disease. Blood 2003; 101:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/58\">",
"      Schwartz AD, Pearson HA. Impaired antibody response to intravenous immunization in sickle cell anemia. Pediatr Res 1972; 6:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/59\">",
"      Kaplan SS, Nardi M. Impairment of leukocyte function during sickle cell crisis. J Reticuloendothel Soc 1977; 22:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/60\">",
"      Winkelstein JA, Drachman RH. Deficiency of pneumococcal serum opsonizing activity in sickle-cell disease. N Engl J Med 1968; 279:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/61\">",
"      Barrett-Connor E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore) 1971; 50:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/62\">",
"      Charache S, Scott JC, Charache P. \"Acute chest syndrome\" in adults with sickle cell anemia. Microbiology, treatment, and prevention. Arch Intern Med 1979; 139:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/63\">",
"      Barrett-Connor E. Acute pulmonary disease and sickle cell anemia. Am Rev Respir Dis 1971; 104:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/64\">",
"      Neumayr L, Lennette E, Kelly D, et al. Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics 2003; 112:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/65\">",
"      Dean D, Neumayr L, Kelly DM, et al. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. J Pediatr Hematol Oncol 2003; 25:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/66\">",
"      Shulman ST, Bartlett J, Clyde WA Jr, Ayoub EM. The unusual severity of Mycoplasmal pneumonia in children with sickle-cell disease. N Engl J Med 1972; 287:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/67\">",
"      Miller ST, Hammerschlag MR, Chirgwin K, et al. Role of Chlamydia pneumoniae in acute chest syndrome of sickle cell disease. J Pediatr 1991; 118:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/68\">",
"      Barrett-Connor E. Pneumonia and pulmonary infarction in sickle cell anemia. JAMA 1973; 224:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/69\">",
"      Haupt HM, Moore GW, Bauer TW, Hutchins GM. The lung in sickle cell disease. Chest 1982; 81:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/70\">",
"      SHELLEY WM, CURTIS EM. Bone marrow and fat embolism in sickle cell anemia and sickle cell-hemoglobin C disease. Bull Johns Hopkins Hosp 1958; 103:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/71\">",
"      Wade LJ, Stevenson LD. Necrosis of the bone marrow with fat embolism in sickle cell anemia. Am J Pathol 1941; 17:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/72\">",
"      Oppenheimer EH, Esterly JR. Pulmonary changes in sickle cell disease. Am Rev Respir Dis 1971; 103:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/73\">",
"      Maitre B, Habibi A, Roudot-Thoraval F, et al. Acute chest syndrome in adults with sickle cell disease. Chest 2000; 117:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/74\">",
"      Kallenbach J, Lewis M, Zaltzman M, et al. 'Low-dose' corticosteroid prophylaxis against fat embolism. J Trauma 1987; 27:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/75\">",
"      Alho A, Saikku K, Eerola P, et al. Corticosteroids in patients with a high risk of fat embolism syndrome. Surg Gynecol Obstet 1978; 147:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/76\">",
"      Lindeque BG, Schoeman HS, Dommisse GF, et al. Fat embolism and the fat embolism syndrome. A double-blind therapeutic study. J Bone Joint Surg Br 1987; 69:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/77\">",
"      Schonfeld SA, Ploysongsang Y, DiLisio R, et al. Fat embolism prophylaxis with corticosteroids. A prospective study in high-risk patients. Ann Intern Med 1983; 99:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/78\">",
"      Walker BK, Ballas SK, Burka ER. The diagnosis of pulmonary thromboembolism in sickle cell disease. Am J Hematol 1979; 7:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/79\">",
"      Sylvester KP, Patey RA, Milligan P, et al. Pulmonary function abnormalities in children with sickle cell disease. Thorax 2004; 59:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/80\">",
"      Ahmed S, Siddiqui AK, Sadiq A, et al. Echocardiographic abnormalities in sickle cell disease. Am J Hematol 2004; 76:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/81\">",
"      Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003; 101:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/82\">",
"      Samuels MP, Stebbens VA, Davies SC, et al. Sleep related upper airway obstruction and hypoxaemia in sickle cell disease. Arch Dis Child 1992; 67:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/83\">",
"      Sidman JD, Fry TL. Exacerbation of sickle cell disease by obstructive sleep apnea. Arch Otolaryngol Head Neck Surg 1988; 114:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/84\">",
"      Strauss T, Sin S, Marcus CL, et al. Upper airway lymphoid tissue size in children with sickle cell disease. Chest 2012; 142:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/85\">",
"      Miller GJ, Serjeant GR, Saunders MJ, et al. Interpretation of lung function tests in the sickle-cell haemoglobinopathies. Thorax 1978; 33:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/86\">",
"      Klings ES, Wyszynski DF, Nolan VG, Steinberg MH. Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med 2006; 173:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/87\">",
"      LEIGHT L, SNIDER TH, CLIFFORD GO, HELLEMS HK. Hemodynamic studies in sickle cell anemia. Circulation 1954; 10:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/88\">",
"      Simmons BE, Santhanam V, Castaner A, et al. Sickle cell heart disease. Two-dimensional echo and Doppler ultrasonographic findings in the hearts of adult patients with sickle cell anemia. Arch Intern Med 1988; 148:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/89\">",
"      Sutton LL, Castro O, Cross DJ, et al. Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994; 74:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/90\">",
"      Suell MN, Bezold LI, Okcu MF, et al. Increased pulmonary artery pressures among adolescents with sickle cell disease. J Pediatr Hematol Oncol 2005; 27:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/91\">",
"      Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 2006; 134:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/92\">",
"      Colombatti R, Maschietto N, Varotto E, et al. Pulmonary hypertension in sickle cell disease children under 10 years of age. Br J Haematol 2010; 150:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/93\">",
"      Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/94\">",
"      Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics 2008; 121:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/95\">",
"      Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/96\">",
"      Mehari A, Gladwin MT, Tian X, et al. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 2012; 307:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/97\">",
"      Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 2006; 296:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/98\">",
"      Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/99\">",
"      Machado RF, Mack AK, Martyr S, et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol 2007; 136:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/100\">",
"      Hsu LL, Champion HC, Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007; 109:3088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/101\">",
"      Bunn HF, Nathan DG, Dover GJ, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010; 116:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/102\">",
"      Gladwin MT, Barst RJ, Castro OL, et al. Pulmonary hypertension and NO in sickle cell. Blood 2010; 116:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/103\">",
"      Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the \"hyperhemolysis paradigm\" for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol 2011; 86:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/104\">",
"      Mori M, Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 2000; 275:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/105\">",
"      Boucher JL, Moali C, Tenu JP. Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization. Cell Mol Life Sci 1999; 55:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/106\">",
"      Jison ML, Gladwin MT. Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Am J Respir Crit Care Med 2003; 168:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/107\">",
"      Kato GJ, Wang Z, Machado RF, et al. Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol 2009; 145:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/108\">",
"      Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/109\">",
"      Morris CR, Kuypers FA, Kato GJ, et al. Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci 2005; 1054:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/110\">",
"      Hagar RW, Morris CR, Vichinsky EP. Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function. Br J Haematol 2006; 133:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/111\">",
"      Kato GJ, Taylor JG 6th. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol 2010; 148:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/112\">",
"      Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005; 294:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/113\">",
"      Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/114\">",
"      Hammerman SI, Klings ES, Hendra KP, et al. Endothelial cell nitric oxide production in acute chest syndrome. Am J Physiol 1999; 277:H1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/115\">",
"      Aslan M, Ryan TM, Townes TM, et al. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J Biol Chem 2003; 278:4194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/116\">",
"      Schacter L, Warth JA, Gordon EM, et al. Altered amount and activity of superoxide dismutase in sickle cell anemia. FASEB J 1988; 2:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/117\">",
"      Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest 1982; 70:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/118\">",
"      Morris CR, Suh JH, Hagar W, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 2008; 111:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/119\">",
"      Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990; 87:9383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/120\">",
"      Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 2007; 175:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/121\">",
"      Aliyu ZY, Suleiman A, Attah E, et al. NT-proBNP as a marker of cardiopulmonary status in sickle cell anaemia in Africa. Br J Haematol 2010; 150:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/122\">",
"      Cho G, Hambleton IR. Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database Syst Rev 2011; :CD008360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/123\">",
"      Hassell KL. Pulmonary hypertension, tricuspid regurgitant velocity screening, and the nitric oxide pathway. Hematology Am Soc Hematol Educ Program 2011; 2011:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/124\">",
"      Minniti CP, Machado RF, Coles WA, et al. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br J Haematol 2009; 147:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/125\">",
"      Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol 2010; 149:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/126\">",
"      Sundaram N, Tailor A, Mendelsohn L, et al. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood 2010; 116:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/127\">",
"      Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005; 130:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/128\">",
"      Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 2005; 90:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/129\">",
"      Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011; 118:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/130\">",
"      Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003; 168:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/131\">",
"      Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol 2000; 111:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/132\">",
"      Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. Br J Haematol 2009; 144:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/133\">",
"      Hagar RW, Michlitsch JG, Gardner J, et al. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol 2008; 140:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/134\">",
"      Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012; 39:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/135\">",
"      Taylor JG 6th, Ackah D, Cobb C, et al. Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol 2008; 83:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/136\">",
"      Dourakis SP, Alexopoulou A, Papageorgiou C, et al. Acute chest syndrome in sickle-cell trait; Two case reports in persons of Mediterranean origin and review of the literature. Eur J Intern Med 2004; 15:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/137\">",
"      Israel RH, Salipante JS. Pulmonary infarction in sickle cell trait. Am J Med 1979; 66:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/138\">",
"      Kark JA, Posey DM, Schumacher HR, Ruehle CJ. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med 1987; 317:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/139\">",
"      Dillard TA, Kark JA, Rajagopal KR, et al. Pulmonary function in sickle cell trait. Ann Intern Med 1987; 106:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/140\">",
"      Bile A, Le Gallais D, Mercier B, et al. Blood lactate concentrations during incremental exercise in subjects with sickle cell trait. Med Sci Sports Exerc 1998; 30:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/141\">",
"      Pearl W, Zeballos RJ, Gregory G, Weisman IM. ECG in sickle cell trait at rest and during exercise and hypoxia. J Electrocardiol 1994; 27:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/142\">",
"      Sara F, Hardy-Dessources MD, Voltaire B, et al. Lactic response in sickle cell trait carriers in comparison with subjects with normal hemoglobin. Clin J Sport Med 2003; 13:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/143\">",
"      Weisman IM, Zeballos RJ, Johnson BD. Cardiopulmonary and gas exchange responses to acute strenuous exercise at 1,270 meters in sickle cell trait. Am J Med 1988; 84:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/144\">",
"      Weisman IM, Zeballos RJ, Johnson BD. Effect of moderate inspiratory hypoxia on exercise performance in sickle cell trait. Am J Med 1988; 84:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/28/27082/abstract/145\">",
"      Weisman IM, Zeballos RJ, Martin TW, Johnson BD. Effect of Army basic training in sickle-cell trait. Arch Intern Med 1988; 148:1140.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7121 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27082=[""].join("\n");
var outline_f26_28_27082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18977349\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute chest syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Preventing recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clinical outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fat and bone marrow embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CHRONIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sickle cell chronic lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Alterations in baseline pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PULMONARY HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13342776\">",
"      Sildenafil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13342783\">",
"      Arginine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SICKLE CELL TRAIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18977349\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7121\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7121|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/52/28494\" title=\"figure 1\">",
"      Formation of NO by NOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7121|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/42/1703\" title=\"picture 1\">",
"      Sickle cell anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9066?source=related_link\">",
"      Acute chest syndrome in adults with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=related_link\">",
"      Fat embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=related_link\">",
"      Inhaled nitric oxide in adults with pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=related_link\">",
"      Sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16810?source=related_link\">",
"      The acute chest syndrome in children and adolescents with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=related_link\">",
"      Vasoocclusion in sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_28_27083="Fatal asthma subtypes";
var content_f26_28_27083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fatal asthma subtypes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rapid onset",
"       </td>",
"       <td class=\"subtitle1\">",
"        Slow onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency",
"       </td>",
"       <td>",
"        8-14 percent",
"       </td>",
"       <td>",
"        86-92 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Triggers",
"       </td>",
"       <td>",
"        Allergen exposure",
"       </td>",
"       <td rowspan=\"4\">",
"        Respiratory tract infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fume or irritant inhalation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise or emotional stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin (ASA) and NSAIDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Pathology",
"       </td>",
"       <td>",
"        Empty, dry airways",
"       </td>",
"       <td>",
"        Mucus filled, wet airways",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutrophil-predominant",
"       </td>",
"       <td>",
"        Eosinophil-predominant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cause of obstruction",
"       </td>",
"       <td>",
"        Bronchoconstriction",
"       </td>",
"       <td>",
"        Mucus plugging &amp; edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recovery",
"       </td>",
"       <td>",
"        Rapid",
"       </td>",
"       <td>",
"        Less rapid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NSAID: nonsteroidal anti-inflammatory agents.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27083=[""].join("\n");
var outline_f26_28_27083=null;
var title_f26_28_27084="HER2 neu response to hormones";
var content_f26_28_27084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of reports that investigated the relationship between endocrine therapy and HER2/neu (c-erbB-2) status",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Technique",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number",
"       </td>",
"       <td class=\"subtitle1\">",
"        HER2/neu-neg, percent response",
"       </td>",
"       <td class=\"subtitle1\">",
"        HER2/neu-pos, percent response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wright 1992",
"       </td>",
"       <td>",
"        Paraffin",
"       </td>",
"       <td>",
"        IHC",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leitzel 1995",
"       </td>",
"       <td>",
"        Serum",
"       </td>",
"       <td>",
"        EIA",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Berns 1995",
"       </td>",
"       <td>",
"        Extract",
"       </td>",
"       <td>",
"        PCR",
"       </td>",
"       <td>",
"        359",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Archer 1995",
"       </td>",
"       <td>",
"        Paraffin",
"       </td>",
"       <td>",
"        IHC",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Newby 1997",
"       </td>",
"       <td>",
"        Paraffin",
"       </td>",
"       <td>",
"        IHC",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yamauchi 1997",
"       </td>",
"       <td>",
"        Serum",
"       </td>",
"       <td>",
"        EIA",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elledge 1998",
"       </td>",
"       <td>",
"        Paraffin",
"       </td>",
"       <td>",
"        IHC",
"       </td>",
"       <td>",
"        205",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Houston 1999",
"       </td>",
"       <td>",
"        Paraffin",
"       </td>",
"       <td>",
"        IHC",
"       </td>",
"       <td>",
"        241",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hayes 2001",
"       </td>",
"       <td>",
"        Serum",
"       </td>",
"       <td>",
"        EIA",
"       </td>",
"       <td>",
"        242",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IHC: immunchistochemistry; EIA: enzyme-linked immunoassay; PCR: polymerase chain reaction.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Ellis MJ, Hayes DF, Lippman ME. Treatment of Metastatic Breast Cancer. In: Diseases of the Breast, 2nd ed, Harris JR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2000. p. 766.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27084=[""].join("\n");
var outline_f26_28_27084=null;
var title_f26_28_27085="Newborn screen trends";
var content_f26_28_27085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Proportion of new diagnoses of cystic fibrosis by newborn screening, 1986-2011",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 282px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cystic Fibrosis Foundation Patient Registry 2011 Annual Data Report, Bethsda, MD. Copyright &copy; 2012 Cystic Fibrosis Foundation. Available at:",
"     <a href=\"file://www.cff.org/UploadedFiles/research/ClinicalResearch/2011-Patient-Registry.pdf\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.cff.org/UploadedFiles/research/ClinicalResearch/2011-Patient-Registry.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27085=[""].join("\n");
var outline_f26_28_27085=null;
var title_f26_28_27086="Ventilatory response to hypoxemia";
var content_f26_28_27086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ventilatory response to hypoxemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ventilation increases in a curvilinear fashion as PO",
"    <sub>",
"     2",
"    </sub>",
"    falls. The data are obtained with PaCO",
"    <sub>",
"     2",
"    </sub>",
"    held constant. Under usual circumstances, the increased ventilation associated with hypoxemia results in a drop in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    , which blunts the ventilatory response. Note that ventilation does not significantly increase until PO",
"    <sub>",
"     2",
"    </sub>",
"    is less than 60 mmHg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hudgel DW, Control of breathing. In: Bronchial Asthma: Mechanisms and Therapeutics, 2d ed, Weiss EB, Segal MS, Stein M (Eds), Little, Brown, Boston, 1984, with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27086=[""].join("\n");
var outline_f26_28_27086=null;
var title_f26_28_27087="Sclerosis in congenital syphilis";
var content_f26_28_27087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Congenital syphilis: Sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse sclerosis with transverse bands of lucency (arrows) in the diaphyses of the femurs and tibias.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg RL. An Atlas of Differential Diagnosis, 4th ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_28_27087=[""].join("\n");
var outline_f26_28_27087=null;
